

## Description

Isolation of the biosynthesis genes for pseudo-oligosaccharides from *Streptomyces glaucescens* GLA.O, and their use

5

The present invention relates to the isolation of genes which encode enzymes for the biosynthesis of  $\alpha$ -amylase inhibitors, so-called pseudo-oligosaccharides. The genes concerned are, in particular, genes from the *Streptomyces* strain *Streptomyces glaucescens* GLA.O (DSM 40716). In addition, this present patent describes the use of these genes for producing acarbose and homologous substances with the aid of *Streptomyces glaucescens* GLA.O, the heterologous expression of these genes in other strains which produce pseudo-oligosaccharides (e.g. *Actinoplanes* sp SE50/100) for the purpose of increasing and stabilizing production, and also their heterologous expression in other microorganisms such as *E. coli*, *Bacillus subtilis*, *Actinomycetales*, such as *Streptomyces*, *Actinoplanes*, *Ampullariella* and *Streptoporangium* strains, *Streptomyces hygroscopicus* var. *limoneus* and *Streptomyces glaucescens*, and also biotechnologically relevant fungi (e.g. *Aspergillus niger* and *Penicillium chrysogenum*) and yeasts (e.g. *Saccharomyces cerevisiae*). The invention also relates to homologous genes in other microorganisms and to methods for isolating them.

*Streptomyces glaucescens* GLA.O produces the two antibiotics hydroxystreptomycin (Hütter (1967) *Systematik der Streptomyceten* (Taxonomy of the *Streptomycetes*). Basel, Karger Verlag) and tetracenomycin (Weber et al. (1979) *Arch. Microbiol.* 121: 111-116). It is known that streptomycetes are able to synthesize structurally varied natural products. However, the conditions under which these compounds are produced are frequently unknown, or else the substances are only produced in very small quantities and not detected.

The  $\alpha$ -amylase inhibitor acarbose has been isolated from a variety of *Actinoplanes* strains (SE50, SE82 and SE18) (Schmidt et al. (1977) *Naturwissenschaften* 64: 535-536). This active substance was discovered in association with screening for  $\alpha$ -amylase inhibitors from organisms of the genera *Actinoplanes*, *Ampullariella* and *Streptosporangium*. Acarbose is pseudotetrasaccharide which is composed of an unusual unsaturated

cyclitol unit to which an amino sugar, i.e. 4,6-dideoxy-4-amino-D-glucopyranose, is bonded. Additional  $\alpha$ -1,4-glycosidically linked D-glucopyranose units can be bonded to the amino sugar. Thus, acarbose, for example, contains two further molecules of D-glucose. The producing strain synthesizes a mixture of pseudo-oligosaccharide products which possess sugar side chains of different lengths (Schmidt et al. (1977) Naturwissenschaften 64: 535-536). The acarbose cyclitol residue is identical to the compound valienamine, which is a component of the antibiotic validamycin A (Iwasa et al. (1979) J. Antibiot. 32: 595-602) from *Streptomyces hygroscopicus* var. *limoneus*.

Acarbose can be produced by fermentation using an *Actinoplanes* strain and has achieved great economic importance as a therapeutic agent for diabetics. While *Actinoplanes* synthesizes a mixture of  $\alpha$ -amylase inhibitor products, it is only the compound having the relative molecular weight of 645.5 (acarviosin containing 2 glucose units (Truscheit (1984) VIIIth International Symposium on Medicinal Chemistry, Proc. Vol. 1. Swedish Academy of Pharmaceutical Sciences, Stockholm, Sweden), which is employed under the generic name of acarbose. The fermentation conditions are selected to ensure that acarbose is the main product of the fermentation. Alternatives are to use particular selectants and strains in which acarbose is formed as the main product or to employ purification processes for achieving selective isolation (Truscheit (1984) VIIIth International Symposium on Medicinal Chemistry, Proc. Vol. 1. Swedish Academy of Pharmaceutical Sciences, Stockholm, Sweden). It is also possible to transform the product mixture chemically in order, finally, to obtain the desired product acarbose.

In contrast to the genus *Streptomyces*, the genus *Actinoplanes* has not so far been investigated intensively from the genetic point of view. Methods which were established for the genus *Streptomyces* are not transferable, or are not always transferable, to the genus *Actinoplanes*. In order to use molecular biological methods to optimize acarbose production in a purposeful manner, the genes for acarbose biosynthesis have to be isolated and characterized. In this context, the possibility suggests itself of attempting to set up a host/vector system for *Actinoplanes* sp. However, this is very tedious and elaborate owing to the fact that studies on *Actinoplanes* have been relatively superficial.

The invention described in the present patent application achieves the object of cloning the biosynthesis genes for acarbose and homologous pseudo-oligosaccharides, with these genes being cloned from  
5 Streptomyces glaucescens GLA.O, which is a streptomycete which has been thoroughly investigated genetically (Crameri et al. (1983) J. Gen. Microbiol. 129: 519-527; Hintermann et al. (1984) Mol. Gen. Genet. 196: 513-520; Motamedi and Hutchinson (1987) PNAS USA 84: 4445-4449; Geistlich et al. (1989) Mol. Microbiol. 3: 1061-1069) and which, surprisingly,  
10 is an acarbose producer. In starch-containing medium, Streptomyces glaucescens GLA.O produces pseudo-oligosaccharides having the molecular weights 645, 807 and 970.

Part of the subject matter of the invention is, therefore, the isolation of the  
15 corresponding biosynthesis genes from Streptomyces glaucescens GLA.O and their use for isolating the adjoining DNA regions in order to complete the gene cluster of said biosynthesis genes.

The isolation of the genes for biosynthesizing pseudo-oligosaccharides, and the characterization of these genes, are of great importance for achieving a better understanding of the biosynthesis of the pseudo-oligosaccharides and its regulation. This knowledge can then be used to increase the productivity of the Streptomyces glaucescens GLA.O strain with regard to acarbose production by means of established classical and  
20 molecular biological methods. In addition to this, the entire gene cluster which encodes the synthesis of the pseudo-oligosaccharides, or individual genes from this gene cluster, can also be expressed in other biotechnologically relevant microorganisms in order to achieve a further increase in, or a simplification of, the preparation of pseudo-oligosaccharides such as acarbose. Specific modification of the  
25 biosynthesis genes can also be used to prepare a strain which exclusively produces acarbose having a molecular weight of 645. Since the genes for biosynthesizing antibiotics are always present in clusters and are often very strongly conserved (Stockmann and Piepersberg (1992) FEMS Microbiol. Letters 90: 185-190; Malpartida et al. (1987) Nature 314:642-644), the  
30 Streptomyces glaucescens GLA.O genes can also be used as a probe for isolating the acarbose-encoding genes from Actinoplanes sp., for example. The expression of regulatory genes, or of genes which encode limiting

steps in the biosynthesis, can result in productivity in *Streptomyces glaucescens* GLA.O, *Actinoplanes* sp. or corresponding producer strains being increased. An increase in productivity can also be achieved by switching off (knocking out or mutagenizing) those acarbose biosynthesis genes which have an inhibitory effect in the biosynthesis.

One possible strategy for cloning antibiotic biosynthesis genes which have not previously been isolated is that of using gene-specific probes (Stockmann and Piepersberg (1992) FEMS Microbiol. Letters 90: 185-190; Malpartida et al. (1987) Nature 314:642-644). These probes can be DNA fragments which are  $P^{32}$ -labeled or labeled in some other way; otherwise, the appropriate genes can be amplified directly from the strains to be investigated using degenerate PCR primers and isolated chromosomal DNA as the template.

The latter method has been employed in the present study. Pseudo-oligosaccharides such as acarbose contain a 4,6-deoxyglucose building block as a structural element. The enzyme dTDP-glucose 4,6-dehydratase is known to be involved in the biosynthesis of 4,6-deoxyglucose (Stockmann and Piepersberg (1992) FEMS Microbiol, Letters 90: 185-190). Since deoxysugars are a frequent constituent of natural products and antibiotics, this enzyme may possibly be a means for isolating the corresponding antibiotic biosynthesis genes. Since these genes are always present as clusters, it is sufficient to initially isolate one gene; the isolation and characterization of the adjoining DNA regions can then be undertaken subsequently.

For example a dTDP-glucose 4,6-dehydratase catalyzes a step in the biosynthesis of hydroxystreptomycin in *Streptomyces glaucescens* GLA.O (Retzlaff et al. (1993) Industrial Microorganisms. Basic and applied molecular genetics ASM, Washington DC, USA). Further dTDP-glucose 4,6-dehydratases have been isolated from other microorganisms, for example from *Streptomyces griseus* (Pissowotzki et al. (1991) Mol. Gen. Genet. 231: 113-123), *Streptomyces fradiae* (Merson-Davies and Cundcliffe (1994) Mol. Microbiol. 13: 349-355) and *Streptomyces violaceoruber* (Bechthold, et al. (1995) Mol. Gen. Genet. 248: 610-620).

It was consequently possible to deduce the sequences for the PCR primers for amplifying a dTDP-glucose 4,6-dehydratase from the amino acid sequences of already known biosynthesis genes. For this, conserved regions in the protein sequences of these enzymes were selected and the amino acid sequences were translated into a nucleic acid sequence in accordance with the genetic code. The protein sequences were taken from the EMBL and Genbank databases. The following sequences were used: Streptomyces griseus; accession number: X62567 gene: strE (dated 10.30.1993); Streptomyces violaceoruber; accession number: L37334 gene: graE (dated 04.10.1995); Saccharopolyspora etythraea; accession number: L37354 gene: gdh (dated 11.09.1994). A large number of possible primer sequences are obtained as a result of the degeneracy of the genetic code. The fact that streptomycetes usually contain a G or C in the third position of a codon (Wright and Bibb (1992) gene 113: 55-65) reduces the number of primers to be synthesized. These primer mixtures can then be used to carry out a PCR amplification with the DNA from strains to be investigated, with the amplification ideally leading to an amplified DNA fragment. In the case of highly conserved proteins, this fragment is of a predictable length which ensues from the distance between the primers in the nucleic acid sequence of the corresponding gene. However, an experimental mixture of this nature does not inevitably have to result in an amplificate. The primers may be too unspecific and amplify a very large number of fragments; alternatively, no PCR product is obtained if there are no complementary binding sites in the chromosome for the PCR primers which have been prepared.

The investigation of the streptomycete strain Streptomyces glaucescens GLA.O resulted in an amplified DNA fragment (acbD) which had the expected length of 550 bp. Further investigation showed that, besides containing a dTDP-glucose 4,6-dehydratase gene for biosynthesizing hydroxystreptomycin, this strain surprisingly contains a second dTDP-glucose 4,6-dehydratase gene for biosynthesizing pseudo-oligosaccharides such as acarbose. While the two genes exhibit a high degree of homology, they are only 65% identical at the amino acid level.

The acbD<sup>\*</sup> probe (see Example 2 and Table 2A) was used to isolate, from Streptomyces glaucescens GLA.O, a 6.8 kb PstI DNA fragment which

encodes a variety of genes (acbA, acbB, acdC, acbD, acbE and acbF) which are involved in the biosynthesis of the pseudo-oligosaccharides.

Deleting the acbBCD genes (aminotransferase, acbB, dTDP-glucose  
5 synthase, acbC, dTDP-glucose 4,6-dehydratase, acbD, see Example 6)  
resulted in the production of a mutant of *Streptomyces glaucescens* GLA.O  
which no longer produces any pseudo-oligosaccharides in the production  
medium. The involvement of the acbBCD genes in the synthesis of  
pseudo-oligosaccharides was therefore verified by deleting the  
10 corresponding loci.

The two genes, i.e. dTDP-glucose synthase and dTDP-glucose 4,6-  
dehydratase, ought to be involved in the biosynthesis of the deoxysugar of  
the pseudo-oligosaccharides, as can be concluded from the function of  
15 thoroughly investigated homologous enzymes (see above). The amino-  
transferase (encoded by the acbB gene) is probably responsible for  
transferring the amino group either to the sugar residue or to the cyclitol  
residue. By analyzing the protein sequence of acbB, an amino acid motif  
was found which is involved in binding pyridoxal phosphate. This motif is  
20 typical of class III aminotransferases (EC 2.6.1.11; EC 2.6.1.13; EC  
2.6.1.18; EC 2.6.1.19; EC 2.6.1.62; EC 2.6.1.64; EC 5.4.3.8). The precise  
enzymic function of acbB can only be elucidated by further investigation of  
the biosynthesis of the pseudo-oligosaccharides. acbE encodes a  
transcription-regulating protein which exhibits a great deal of similarity to  
25 DNA-binding proteins which possess a helix-turn-helix motif (e.g. *Bacillus*  
*subtilis* DegA, P37947: Swiss-Prot database). Thus, the transcription  
activator CcpA from *Bacillus subtilis* inhibits the formation of  $\alpha$ -amylase in  
the presence of glucose, for example (Henkin et al. (1991) *Mol. Microbiol.*  
5: 575-584). Other representatives of this group are proteins which  
30 recognize particular sugar building blocks and are able to exhibit a positive  
or negative effect on the biosynthesis of metabolic pathways. The  
biosynthesis of the pseudo-oligosaccharides is also regulated in  
*Streptomyces glaucescens* GLA.O. It was only previously possible to  
demonstrate the synthesis of pseudo-oligosaccharides on starch-  
35 containing media. While this method indicated that AcbE might be  
responsible for regulating pseudo-oligosaccharide synthesis, the precise  
mechanism is still not known. However, molecular biological methods can  
now be used to modify the gene specifically in order to obtain an increased

rate of pseudo-oligosaccharide biosynthesis. Furthermore, the DNA site at which *acbE* binds can be identified by means of so-called gel shift assays (Miwa et al. (1994) Microbiology 140: 2576-2575). An increase in the rate at which acarbose is biosynthesized can be achieved after identifying and then modifying the promoters and other regulatory DNA regions which are responsible for the transcription of the pseudo-oligosaccharide genes.

At present, the function of *acbF* is still not definitely known. The corresponding gene product exhibits homologies with sugar-binding proteins such as the sugar-binding protein from *Streptococcus mutans* (MsmE; Q00749: Swissprot database), making it probable that it is involved in the biosynthesis of the pseudo-oligosaccharides. The gene product of the *acbA* gene exhibits homologies with known bacterial ATP-binding proteins (e.g. from *Streptomyces peucetis* DrrA, P32010: SwissProt database). The *AcbA* protein possesses the typical ATP/GTP binding motif, i.e. the so-called P loop. These proteins constitute an important component of so-called ABC transporters, which are involved in the active transport of metabolites at biological membranes (Higgins (1995) Cell 82: 693-696). Accordingly, *AcbA* could be responsible for exporting pseudo-oligosaccharides out of the cell or be involved in importing sugar building blocks for biosynthesizing  $\alpha$ -amylase inhibitors such as maltose.

All streptomycete genes for biosynthesizing secondary metabolites which have so far been analyzed are arranged in a cluster. For this reason, it is to be assumed that the acarbose biosynthesis genes according to the application are also arranged in such a gene cluster. The remaining genes which are relevant for pseudo-oligosaccharide biosynthesis can therefore also be isolated by isolating the DNA regions which adjoin the 6.8 kb *Pst*I DNA fragment according to the invention. As has also already been mentioned above, it is readily possible to isolate homologous gene clusters from microorganisms other than *Streptomyces glaucescens* GLA.O.

The invention therefore relates to a recombinant DNA molecule which comprises genes for biosynthesizing acarbose and homologous pseudo-oligosaccharides, in particular a recombinant DNA molecule in which individual genes are arranged, with respect to their direction of transcription and order, as depicted in Figure 3 and/or which exhibits a restriction

enzyme cleavage site pattern as depicted in Figure 3, and, preferably, to a recombinant DNA molecule which

- (a) comprises a DNA sequence according to Table 4, or parts thereof;
- (b) comprises a DNA sequence which is able to hybridize, under  
5 stringent conditions, with the DNA molecule according to (a), or parts thereof; or
- (c) comprises a DNA sequence which, because of the degeneracy of the genetic code, differs from the DNA molecules according to (a) and (b) but which permits the expression of the proteins which can  
10 be correspondingly expressed using the DNA molecule according to (a) and (b), or parts thereof.

The invention furthermore relates to a recombinant DNA molecule which comprises the *acbA* gene, in particular which is characterized in that it  
15 comprises the DNA sequence of nucleotides 1 to 720 according to Table 4, or parts thereof; to a recombinant DNA molecule which comprises the *acbB* gene, in particular which is characterized in that it comprises the DNA sequence of nucleotides 720 to 2006 according to Table 4, or parts thereof; to a recombinant DNA molecule which comprises the *acbC* gene,  
20 in particular which is characterized in that it comprises the DNA sequence of nucleotides 2268 to 3332 according to Table 4, or parts thereof; to a recombinant DNA molecule which comprises the *acbD* gene, in particular which is characterized in that it comprises the DNA sequence of nucleotides 3332 to 4306 according to Table 4, or parts thereof; to a  
25 recombinant DNA molecule which comprises the *acbE* gene, in particular which is characterized in that it comprises the DNA sequence of nucleotides 4380 to 5414 according to Table 4, or parts thereof; and to a recombinant DNA molecule which comprises the *acbF* gene, in particular which is characterized in that it comprises the DNA sequence of  
30 nucleotides 5676 to 6854 according to Table 4, or parts thereof.

The invention furthermore relates to oligonucleotide primers for the PCR amplification of a recombinant DNA molecule which is as described above and which comprises genes for biosynthesizing acarbose and homologous  
35 pseudo-oligosaccharides, with the primers having, in particular, the sequence according to Table 1.



The invention furthermore relates to a vector which comprises a recombinant DNA molecule which comprises a DNA molecule as described in the penultimate and prepenultimate paragraphs, in particular which is characterized in that the vector is an expression vector and said DNA molecule is linked operatively to a promoter sequence, with the vector preferably being being suitable for expression in host organisms which are selected from the group consisting of *E. coli*, *Bacillus subtilis*, Actinomycetales, such as *Streptomyces*, *Actinoplanes*, *Ampullariella* and *Streptosporangium* strains, *Streptomyces hygroscopicus* var. *limoneus*, *Streptomyces glaucescens* and also biotechnologically relevant fungi (e.g. *Aspergillus niger*, *Penicillium chrysogenum*) and yeasts (e.g. *Saccharomyces cerevisiae*), with *Streptomyces glaucescens* GLA.O or *Actinoplanes* sp. being very particularly preferred. Since the operative linkage of said DNA molecule to promoter sequences of the vector is only one preferably embodiment of the invention, it is also possible for expression to be achieved using promoter sequences which are endogenous in relation to the DNA molecule, e.g. the promoters which are in each case natural, or the natural promoters which have been mutated with regard to optimizing the acarbose yield. Such natural promoters are part of the DNA molecule according to the invention.

The invention furthermore relates to a vector which comprises a DNA molecule according to the invention for use in a process for eliminating or altering natural acarbose biosynthesis genes in an acarbose-producing microorganism. Such a vector is preferably selected from the group consisting of pGM160 and vectors as described in European Patents EP 0 334 282 and EP 0 158 872.

The invention furthermore relates to a host cell which is transformed with one of the above-described DNA molecules or vectors, in particular characterized in that said host cell is selected from the group consisting of *E. coli*, *Bacillus subtilis*, Actinomycetales, such as *Streptomyces*, *Actinoplanes*, *Ampullariella* or *Streptosporangium* strains, *Streptomyces hygroscopicus* var. *limoneus* or *Streptomyces glaucescens*, and also biotechnologically relevant fungi (e.g. *Aspergillus niger* and *Penicillium chrysogenum*) and yeasts (e.g. *Saccharomyces cerevisiae*); it is very particularly preferred for it to be selected from the group consisting of *Streptomyces glaucescens* GLA.O and *Actinoplanes* sp.

The invention furthermore relates to a protein mixture which can be obtained by expressing the genes of the recombinant DNA molecule according to the invention, comprising genes for biosynthesizing acarbose and homologous pseudo-oligosaccharides, in particular characterized in that the DNA molecule

- 5 (a) comprises a DNA sequence according to Table 4, or parts thereof;
- (b) comprises a DNA sequence which is able to hybridize, under stringent conditions, with the DNA molecule according to (a) or parts thereof; or
- 10 (c) comprises a DNA sequence which, because of the degeneracy of the genetic code, differs from the DNA molecules according to (a) and (b) but which permits the expression of the proteins which can correspondingly be expressed using the DNA molecule according to (a) and (b), or parts thereof.

15

The invention furthermore relates to isolated proteins which can be obtained by expressing the genes which are encoded by the DNA molecule described in the previous paragraph.

- 20 The following statements apply to all the individual genes identified within the context of the present invention and have only been brought together for reasons of clarity: the invention furthermore relates to a protein which is encoded by a recombinant DNA molecule as described in the last paragraph but one, in particular characterized in that it comprises the DNA
- 25 sequence of nucleotides 1 to 720 or 720 to 2006 or 2268 to 3332 or 3332 to 4306 or 4380 to 5414 or 5676 to 6854 according to Table 4 or parts thereof; a protein is very particularly preferred which is encoded by the acbA gene or the acbB gene or the acbC gene or the acbD gene or the acbE gene or the acbF gene, and which comprises the amino acid
- 30 sequence according to Table 4 or parts thereof.

The invention furthermore relates to a process for obtaining the proteins which were described above as being part of the subject-matter of the invention, which process is characterized in that

- 35 (a) the proteins are expressed in a suitable host cell, in particular which is characterized in that said host cell is selected from the group consisting of *E. coli*, *Bacillus subtilis*, Actinomycetales, such as *Streptomyces*, *Actinoplanes*, *Ampullariella* or *Streptosporangium*

- 5 strains, *Streptomyces*, *hygroscopicus* var. *limoneus* or *Streptomyces glaucescens*, and also biotechnologically relevant fungi (e.g. *Aspergillus niger* and *Penicillium chrysogenum*) and yeasts (e.g. *Saccharomyces cerevisiae*); with the host cell very particularly preferably being selected from the group consisting of *Streptomyces glaucescens* GLA.O and *Actinoplanes* sp., and
- (b) are isolated.

10 The invention furthermore relates to a process for preparing acarbose, characterized in that

- (a) one or more genes of the recombinant DNA molecule which comprises a DNA sequence according to Table 4 or parts thereof or which comprises a DNA sequence which is able to hybridize, under stringent conditions, with the DNA molecule according to Table 4, or
- 15 parts thereof, or which comprises a DNA sequence which, because of the degeneracy of the genetic code, differs from the DNA molecules which have just been described but which permits the expression of the proteins which can be correspondingly expressed using these DNA molecules, or parts thereof, is/are used for
- 20 expression in a suitable host cell which is selected, in particular, from the same group as in the last paragraph, and
- (b) the acarbose is isolated from culture supernatants of said host cell.

25 The invention furthermore relates to a process for preparing acarbose, characterized in that

- (a) one or more genes of the recombinant DNA molecule which comprises a DNA sequence according to Table 4 or parts thereof or which comprises a DNA sequence which is able to hybridize, under stringent conditions, with the DNA molecule according to Table 4, or
- 30 parts thereof, or which comprises a DNA sequence which, because of the degeneracy of the genetic code, differs from the DNA molecules which have just been described but which permits expression of the proteins which can be correspondingly expressed using the DNA molecules, or parts thereof, are eliminated in an
- 35 acarbose-producing host cell, in particular *Streptomyces glaucescens* GLA.O and *Actinoplanes* sp., and
- (b) the acarbose is isolated from said host cell.

In this connection, the elimination of one or more genes can be effected by means of standard molecular biological methods, for example using the above-described vectors (pGM160 and others). A gene to be eliminated could, for example, be the *acbE* gene, which probably has a regulatory function. Genes could likewise be eliminated with the aim of obtaining pure acarbose as the only fermentation product and no longer obtaining a mixture of homologous pseudo-oligosaccharides (see above). The elimination of said genes is preferably achieved using the vectors which have been described above for this purpose.

10

The invention furthermore relates to a process for preparing acarbose, characterized in that the processes for preparing acarbose which have been described in the previous two paragraphs are combined with each other, such that, therefore, one or more of said genes is/are expressed artificially and one or more of said genes is/are eliminated.

The invention furthermore relates to a process for altering the gene expression of endogenous acarbose biosynthesis genes by mutating the respective gene promoter in order to obtain improved yields of acarbose. In this context, known methods of homologous recombination can be used to introduce the mutations into the production strain to be improved. These mutations can be transitions, deletions and/or additions. An "addition" can, for example, denote the addition of one single nucleotide or several nucleotides or of one or more DNA sequences which have a positive regulatory effect and which bring about an enhancement of the expression of an endogenous gene for biosynthesizing acarbose. The converse case, i.e. the addition of a DNA sequence which has a negative regulatory effect for repressing an endogenous acarbose biosynthesis gene is also a preferred form of an addition. "Transitions" may, for example, be nucleotide exchanges which reduce or amplify the effect of regulatory elements which act negatively or positively. "Deletions" can be used to remove regulatory elements which act negatively or positively. The endogenous genes of this process are preferably present in Actinomycetales, such as Streptomyces, Actinoplanes, Ampullariella or Streptosporangium strains, Streptomyces hygroscopicus var. limoneus or Streptomyces glaucescens; very particularly, they are present in Streptomyces glaucescens GLA.O and Actinoplanes sp.

The invention furthermore relates to the use of *Streptomyces* GLA.O for obtaining acarbose.

5 The invention furthermore relates to the use of *Streptomyces* GLA.O for preparing mutants of this strain by the "classical route", which mutants make it possible to achieve a more abundant production of acarbose. The methods for preparing improved natural product producers of this nature have been known for a long time and frequently make use of classical steps of mutagenesis and selection.

10

The invention furthermore relates to a process for completing the gene cluster for biosynthesizing acarbose and homologous polysaccharides according to Table 4, characterized in that

- 15 a) hybridization probes which are derived from the DNA molecule according to Table 4 are prepared,
- b) these hybridization probes are used for the genomic screening of DNA libraries obtained from *Streptomyces glaucescens* GLA.O, and
- c) the clones which are found are isolated and characterized.

20 The invention furthermore relates to a process for completing the gene cluster for biosynthesizing acarbose and homologous pseudo-oligosaccharides according to Table 4, characterized in that, proceeding from the recombinant DNA molecule according to Table 4,

- a) PCR primers are prepared,
- 25 b) these PCR primers are used to accumulate DNA fragments of genomic DNA from *Streptomyces glaucescens* GLA.O, with these primers being combined with those primers which hybridize from sequences of the vector system employed,
- c) the accumulated fragments are isolated and characterized.

30

The invention furthermore relates to a process for isolating a gene cluster for biosynthesizing acarbose and homologous pseudo-oligosaccharides from acarbose-producing microorganisms other than *Streptomyces glaucescens* GLA.O, characterized in that, proceeding from the recombinant DNA molecule according to Claim 4,

35

- a) hybridization probes are prepared,

- b) these hybridization probes are used for the genomic or cDNA screening of DNA libraries which have been obtained from the corresponding microorganism, and
- c) the clones which are found are isolated and characterized.

5

The invention furthermore relates to a process for isolating a gene cluster for biosynthesizing acarbose and homologous pseudo-oligosaccharides from acarbose-producing microorganisms other than *Streptomyces glaucescens* GLA.O, characterized in that, proceeding from the recombinant DNA molecule according to Claim 4,

10

- a) PCR primers are prepared,
- b) these PCR primers are used for accumulating DNA fragments of genomic DNA or cDNA from a corresponding microorganism,
- c) the accumulated fragments are isolated and characterized, and
- 15 d) where appropriate, employed in a process as described in the previous paragraph.

20

The described processes for isolating a gene cluster for the biosynthesis of acarbose and homologous pseudo-oligosaccharides from acarbose-producing microorganisms other than *Streptomyces glaucescens* GLA.O are characterized in that the microorganisms are selected from the group consisting of Actinomycetales, such as *Streptomyces*, *Actinoplanes*, *Ampullariella* and *Streptosporangium* strains, *Streptomyces hygroscopicus* var. *limoneus* and *Streptomyces glaucescens*, preferably from the group consisting of *Streptomyces glaucescens* GLA.O and *Actinoplanes* sp.

25

The invention furthermore relates to the use of *Streptomyces glaucescens* GLA.O for isolating acarbose.

- 30 The invention will now be explained in more detail with the aid of the examples, tables and figures, without being restricted thereto.

All the plasmid isolations were carried out using a Macherey and Nagel (Düren, Germany) isolation kit (Nucleobond<sup>®</sup>) in accordance with the manufacturer's instructions. Molecular biological procedures were carried out in accordance with standard protocols (Sambrook et al. (1989) Molecular cloning: A Laboratory Manual, 2nd ed. Cold Spring Harbor Laboratory, USA) or in accordance with the instructions of the respective

35

manufacturer. DNA and protein sequences were examined using Genetics Computer Group Software, Version 8 (programs: FastA, TFastA, BlastX, Motifs, GAP and CODONPREFERENCE) and the SwissProt (release 32), EMBL (release 46) and Prosite (release 12.2) databases. The molecular biological manipulation of *Streptomyces glaucescens* and *Actinoplanes* (DNA isolation and DNA transformations) were carried out as described in Hopwood et al.: Genetic Manipulation of *Streptomyces*: A Laboratory Manual. The John Innes Foundation, Norwich, UK, 1985 and Motamedi and Hutchinson: Cloning and heterologous expression of a gene cluster for the biosynthesis of tetracenomycin C, the anthracycline antitumor antibiotic of *Streptomyces glaucescens*. Proc. Natl. Acad. Sci. USA 84:4445-4449 (1987).

In general, hybridizations were performed using the "Non-radioactive DNA labeling kit" from Boehringer Mannheim (Cat. No. 1175033). The DNA was visualized using the "Luminescent Detection Kit" from Boehringer Mannheim (Cat. No. 1363514). In all the examples given in this patent application, hybridization was carried out under stringent conditions: 68°C, 16 h. 5×SSC, 0.1% N-laurylsarcosine, 0.02% SDS, 1% Blocking Reagent (Boehringer Mannheim). SSC denotes 0.15M NaCl/0.015M sodium citrate. The definition of "stringent conditions" which is given here applies to all aspects of the present invention which refer to "stringent conditions". In this connection, the manner of achieving this stringency, i.e. the cited hybridization conditions, is not intended to have a limiting effect since the skilled person can select other conditions as well in order to achieve the same stringent conditions, e.g. by means of using other hybridization solutions in combination with other temperatures.

Example 1: Synthesis and sequences of the PCR primers and amplification of the fragments from *S. glaucescens* GLA.O

The PCR was carried out under standard conditions using in each case 100 pmol of primer 1 and of primer 2 in 100 µl of reaction mixture

35	PCR buffer <sup>1</sup>	10 µl
	PCR primers	in each case 2.5 µl
	dNTPs	in each case 0.2 mM
	BSA (10 mg/ml)	1 µl

Template DNA	1 µg (1 µl)
Taq polymerase <sup>2</sup> (5 units/ml)	1.5 µl
H <sub>2</sub> O	to make up to 100 µl
<sup>1</sup> : Promega	
5 <sup>2</sup> : Boehringer Mannheim	

The samples are overlaid with 75 µl of mineral oil and the amplification is carried out using a Perkin Elmer TC1 DNA thermal cycler.

#### 10 Parameters:

Cycles	Temperature	Duration
1	96°C	5 min
	74°C	5 min
30	95°C	1.5 min
	74°C	1.5 min
1	74°C	5 min

Table 1 lists the sequences of the degenerate primers which should be used for amplifying dTDP-glucose dehydratases from different streptomycetes.

Table 1: Primer sequences for amplifying dTDP-glucose 4,6-dehydratases

20 Primer 1: CSGGSGSSGCSGGSTTCATSGG (SEQ ID NO.: 1)

Primer 2: GGGWVCTGGYVSGGSCCGTAGTTG (SEQ ID NO.: 2)

In this table, S=G or C, W=A or T, V=A or G, and Y=T or C.

25

Example 2: DNA sequences of the PCR fragments isolated from *Streptomyces glaucescens* GLA.O

30 The sequencing was performed by the dideoxy chain termination method of Sanger et al. (PNAS USA, 74: 5463-5467 (1977)). The reactions were carried out using the Auto Read Sequencing Kit<sup>®</sup> from Pharmacia Biotech (Freiburg, Germany) in accordance with the manufacturer's instructions. An



ALF DNA Sequencer<sup>®</sup> from Pharmacia Biotech (Freiburg, Germany) was used for separation and detection.

The subsequent cloning of the PCR fragments (Sure Clone Kit<sup>®</sup>, Pharmacia Biotech, Freiburg) into the E. coli vector pUC 18, and the sequencing of the fragment, provided support for the supposition that the fragment encoded a dTDP-glucose 4,6-dehydratase. However, 2 different genes were isolated which both exhibit high degrees of homology with dTDP-glucose 4,6-dehydratase but are not identical. In that which follows, the PCR fragments are designated *acbD*<sup>\*</sup> and *HstrE*<sup>\*</sup>.

The sequences of the isolated PCR fragments are shown in Table 2A and 2B and the homology comparison of the deduced amino acid sequences of *HstrE*<sup>\*</sup> and *acbD*<sup>\*</sup> is shown in Table 2C. The two proteins exhibit an identity of only 65%.

Table 2A: DNA sequence of *acbD*<sup>\*</sup> (primer-binding sites are underlined, SEQ ID NO.: 3)

Primer 1

```
1  CCCGGGGCGGG CGGGGGTTCA TCGGCTCCGC CTACGTCCGC CGGCTCCTGT
51  CGCCCGGGGC CCCCGGCGGC GTCGCGGTGA CCGTCCTCGA CAAACTCACC
101 TACGCCGGCA GCCTCGCCCG CCTGCACGCG GTGCGTGACC ATCCGGGCCT
151 CACCTTCGTC CAGGGCGACG TGTGCGACAC CGCGCTCGTC GACACGCTGG
201 CCGCGCGGCA CGACGACATC GTGCACTTCG CGGCCGAGTC GCACGTGAC
251 CGCTCCATCA CCGACAGCGG TGCCTTCACC CGCACCAACG TGCTGGGCAC
301 CCAGGTCCTG CTCGACGCCG CGCTCCGCCA CGGTGTGCGC ACCCTCGTGC
351 ACGTCTCCAC CGACGAGGTG TACGGCTCCC TCCCGCACGG GGCCGCCGCG
401 GAGAGCGACC CCCTGCTCCC GACCTCGCCG TACGCGGCGT CGAAGGCGGC
451 CTCGGACCTC ATGGCGCTCG CCCACCACCG CACCCACGGC CTGGACGTCC
501 GGGTGACCCG CTGTTCTGAAC AACTACGGCC CGCACCAGTT CCGGGG
```

Primer 2

Table 2B: DNA sequence of HstrE\* (primer-binding sites are underlined, SEQ ID NO.: 4)

Primer 2

```

1  CCCCGGGTGC TGGTAGGGGC CGTAGTTGTT GGAGCAGCGG GTGATGCGCA
51  CGTCCAGGCC GTGGCTGACG TGCATGGCCA GCGCGAGCAG GTCGCCCCGAC
101 GCCTTGGAGG TGGCATAGGG GCTGTTGGGG CGCAGCGGCT CGTCCTCCGT
151 CCACGACCCC GTCTCCAGCG AGCCGTAGAC CTCGTCGGTG GACACCTGCA
201 CGAAGGGGGC CACGCCGTGC CGCAGGGCCG CGTCGAGGAG TGTCTGCGTG
251 CCGCCGGCGT TGGTCCGCAC GAACGCGGCG GCATCGAGCA GCGAGCGGTC
301 CACGTGCGAC TCGGCGGCGA GGTGCACGAC CTGGTCCTGG CCGGCCATGA
351 CCCGGTCGAC CAGGTCCGCG TCGCAGATGT CGCCGTGGAC GAAGCGCAGC
401 CGGGGGTGGT CGCGGACCGG GTCGAGGTTG GCGAGGTTGC CGGCGTAGCT

451 CAGGGCGTCG AGCACGGTGA CGACGGCGTC GGGCGGCCCC TCCGGACCGA
501 GGAGGGTGCG GACGTAGTGC GAGCCCATGA ACCCGCCCCG C

```

Primer 1

5

Table 2C: Homology comparison of the deduced amino acid sequences of the PCR products HstrE\* and acbD\* (program: GAP)

Quality:	196.3	Length:	182
Ratio:	1.091	Gaps:	0
Percent similarity:	77.654	Percent identity:	65.363

# 10 PCRstrE.Pep × PCRacbD.Pep

```

1  ..AAGFMGSHYVRTLLGPDGPPDAVVTVLDALSYAGNLANLDPVRDHPRL 48
   :||:| | | | | :|:|:| | :|:|:| | | | | | | | | | | | | | | | |
1  PGGAGFIGSAYVRLLSPGAPGGVAVTVLDKLTYAGSLARLHAVRDHPGL 50

49 RFVHGDI CDADLVDRVMAGQDQVVHLAAESHVDRSLLDAAAFVRTNAGGT 98
   ||:|:| | | | | : | :|:|:| | | | | | | | | | | | | | | |
51 TFVQGDVCDTALVDTLAARHDDIVHFAAESHVDRSITDSGAFTRTNVLGT 100

99 QTL LDAALRHGVAPFVQVSTDEVYGSLETGSWTEDEPLRPNSPYATSKAS 148
   |. | | | | | | | | | | :|:|:| | | | | | | | | | | | | | | |
101 QVLLDAALRHGVRTLHVSTDEVYGS LPHGAAAESDPLLPTSPYAASKAA 150

149 GDLLALAMHVSHGLDVRITRCSNNGPYQHPG 180
   :|:|:| | | | | | | | | | | | | | | | | | | | | | | |
151 SDLMA LAHHRTHGLDVRVTRCSNNGPHQFP. 181

```

in each case, upper row: SEQ ID NO.: 5

in each case, lower row: SEQ ID NO.: 6

Example 3: Southern analysis using chromosomal DNA from *Streptomyces glaucescens* GLA.O and the isolated and labeled PCR fragments

- 5 The cells were grown in R2YENG medium and harvested for the DNA isolation after 30 h. The chromosomal DNA was isolated from *S. glaucescens* GLA.O as described in Hopwood et al. (1985) Genetic manipulations of *Streptomyces*: a laboratory manual. The John Innes Foundation, Norwich UK).

10

- A Southern blot analysis was carried out using the *S. glaucescens* GLA.O producer strain chromosomal DNA, which was digested with PstI, BglII and BamHI, using the labeled probes consisting of the *acbD* and *HstrE* PCR fragments. The two PCR fragments were labeled with digoxigenin in accordance with the manufacturer's (Boehringer Mannheim; Mannheim) instructions, and a digest of the *Streptomyces glaucescens* GLA.O producer strain chromosomal DNA was separated on an agarose gel. The DNA was transferred by capillary transfer to nylon membranes and DNA regions which were homologous with the labeled probes were subsequently visualized following hybridization.
- 15
- 20

- The two genes label different DNA regions (Fig. 1 and Fig. 2), with the fragments which were labeled by *HstrE* having to be gene fragments from *Streptomyces glaucescens* GLA.O hydroxystreptomycin biosynthesis.
- 25 While the DNA sequence is not published, the high degree of homology of the protein sequence deduced from *HstrE* with *StrE* (Pissowotzki et al. (1991) Mol. Gen. Genet. 231: 113-123) from *Streptomyces griseus* N2-3-11 streptomycin biosynthesis (82% identity) and the concordance of the *HstrE* -labeled DNA fragments (Fig. 1) with the published restriction map of the *Streptomyces glaucescens* GLA.O hydroxystreptomycin gene cluster (Retzlaff et al. (1993) Industrial Microorganisms. Basic and applied molecular genetics ASM, Washington DC, USA) permits this conclusion.
- 30 The fragments which were labeled by the *acbD* probe (Fig. 2) belong to a DNA region which has not previously been investigated. This region encodes the enzymes for biosynthesizing the *Streptomyces glaucescens* GLA.O pseudo-oligosaccharides.
- 35

#### Example 4: Cloning the 6.8 kb PstI fragment

Inter alia, the *acbD*<sup>\*</sup> PCR fragment labels a 6.8 kB PstI DNA fragment (Fig. 2). This DNA fragment was isolated as follows. The region of the gel was excised with a razor blade and the DNA was isolated from the gel using an isolation kit from Pharmacia Biotech and cloned into plasmid pUC19 which had been cut with the restriction enzyme PstI (plasmid *pacb1*); this latter plasmid was then transformed into the *E. coli* strain DH5 $\alpha$ . The individual clones were subcultured from these plates and a plasmid DNA isolation was carried out using these clones. A PCR amplification using the above-described primers 1 and 2 (Tab. 1) was carried out using the DNA from these clones (250). In this manner, the appropriate *E. coli* clone containing the 6.8 kb PstI fragment was isolated.

#### 15 Example 5: Sequencing the isolated 6.8 kb PstI DNA fragment

The DNA was digested with various restriction enzymes and individual DNA fragments were cloned into pUC19. The DNA sequence of the entire fragment, which is shown in Tab. 4 (SEQ ID NO.: 7), was then determined.

20 The DNA sequence of the 6.8 kb PstI fragment was only partially confirmed by supplementary sequencing of the opposing strand. Several open reading frames, encoding various proteins, were found (programs: CODONPREFERENCE and BlastX). A total of 6 coding regions was found, i.e. a gene having a high degree of homology with ATP-binding protein, *acbA*, an aminotransferase *acbB*, a dTDP-glucose synthase *acbC*, a dTDP-glucose dehydratase *acbD*, a regulatory gene having homologies with the LacI protein family *acbE*, and a protein having similarities to sugar-binding proteins *acbF*. The sequences of the *acbA* and *acbF* genes were only determined in part. The homologies with other proteins from the databases, and the properties of the putative proteins, are summarized in

30 Tab. 3. Fig. 3 shows, in summary form, a restriction map of the fragment, containing the most important restriction cleavage sites mentioned in the text, and the arrangement of the identified open reading frames.

Table 3: Analysis of the identified open reading frames on the 6.8 kb PstI fragment from *Streptomyces glaucescens* GLA.O

ORF	Amino acid	MW	FastA <sup>§</sup>	%Identity	Accession number <sup>§</sup>
acbA	239	.	MalK E coli	29%	P02914
acbB	429	45618	DgdA, Burkholderia cepacia	32%	P16932
acbC	355	37552	StrD, Streptomyces griseus	60%	P08075
acbD	325	35341	StrE, Streptomyces griseus	62%	P29782
acbE	345	36549	DegA, Bacillus subtilis	31%	P37947
acbF	396	.	MalE, E. coli	22%	P02928

5 \* incomplete open reading frame; § Swiss-Prot database (release 32)

Example 6: Deletion of genes acbBCD for pseudo-oligosaccharide biosynthesis from the *Streptomyces glaucescens* GLA.O chromosome

10

Evidence that the identified DNA fragment encoded pseudo-oligosaccharide biosynthesis genes was produced as follows. A 3.4 kb gene region (EcoRI/SstI fragment b, Fig. 3) was replaced with the erythromycin resistance gene (1.6 kb) and cloned, together with flanking DNA regions from the 6.8 kb PstI fragment (pacb1) into the temperature-sensitive plasmid pGM160. The plasmid was constructed as described in the following: the 2.2 kb EcoRI/HindIII fragment (c, Fig. 3) from plasmid pacb1 was cloned into pGEM7zf (Promega, Madison, WI, USA; plasmid pacb2), and the 1 kb SstI fragment from pacb1 (a, Fig. 3) was cloned into pUC19 (plasmid pacb3). A ligation was then carried out using the following fragments. The plasmid pGM160 (Muth et al. (1989) Mol. Gen Genet. 219:341-348) was cut with BamH/HindIII, the plasmid pacb2 was cut with XbaI/BamHI (c, Fig. 3), the plasmid pacb3 was cut with EcoRI/HindIII (a, Fig 3), and the plasmid pIJ4026 (Bibb et al. (1985) Gene 38:215-226) was cut with EcoRI/XbaI in order to isolate the 1.6 kb ermE resistance gene.

15

20

25

The fragments were ligated in a mixture and transformed into *E. coli* DH5 $\alpha$  and selected on ampicillin. The resulting plasmid, i.e. pacb4, was isolated from *E. coli* DH5 $\alpha$ , tested for its correctness by means of restriction digestion and then transferred by protoplast transformation into

5 *S. glaucescens* GLA.O. The transformants were selected with thiostrepton at 27°C in R2YENG agar. The transformants were subsequently incubated at the non-permissive temperature of 39°C and integration of the plasmid into the genome by way of homologous recombination thereby instituted (selection with thiostrepton (25  $\mu$ g/ml) and erythromycin (50  $\mu$ g/ml)). Under

10 these conditions, the only clones which can grow are those in which the plasmid has become integrated into the genome. The corresponding clones were isolated, caused to sporulate (medium 1, see below) and plated out on erythromycin-containing agar (medium 1). Individual clones were isolated once again from this plate and streaked out on both

15 thiostrepton-containing medium and erythromycin-containing medium. The clones which were erythromycin-resistant but no longer thiostrepton-resistant were analyzed. In these clones, the acbBCD genes had been replaced with ermE. Several clones were examined and the strain *S. glaucescens* GLA.O  $\Delta$ acb was finally selected as the reference strain

20 (erythromycin-resistant, thiostrepton-sensitive) for further investigation.

#### Medium 1

	Yeast extract	4 g/L
25	Malt extract	10 g/L
	Glucose	4 g/L
	Agar	15 g/L
	pH	7.2

30 A further experiment examined whether the corresponding strain still produced acarbose. Some clones were grown and investigated for formation of the  $\alpha$ -amylase inhibitor in a bioassay; however, no activity was found. The mutants were subsequently further characterized by means of Southern hybridization. Integration of the ermE gene had taken place at

35 the predicted site. Fig. 4 shows a Southern hybridization which was carried out with the wild type and with the *Streptomyces glaucescens* GLA.O  $\Delta$ acb deletion mutant. The SstI fragment from pacb3 was used as the probe. The chromosomal DNA was isolated from the wild type and mutant and

digested with the enzymes PstI and PstI/HindIII. The fragment pattern obtained for the deletion mutant corresponds to the predicted recombination event. The wild type exhibits the unchanged 6.8 kb PstI fragment, whereas the mutant exhibits a fragment which has been truncated by 1.8 kb (compare lanes 1 and 3, Fig. 4). Integration of the ermE resistance gene additionally introduced an internal HindIII cleavage site into the PstI fragment (compare lanes 2 and 4, Fig. 4).

#### Example 7: Inhibition of $\alpha$ -amylase by acarbose

10

Using an enzymic test for detecting starch (TC-Starch, Boehringer-Mannheim, Cat. No. 297748), it was possible to demonstrate that the compound isolated from *Streptomyces glaucescens* GLA.O inhibits  $\alpha$ -amylase. Test principle: starch is cleaved into D-glucose by amyloglucosidase. The glucose is then converted with hexokinase into glucose-6-phosphate and the latter is converted with glucose-6-phosphate dehydrogenase into D-gluconate-6-phosphate. This reaction produces NADPH, whose formation can be determined photometrically. Acarbose inhibits the  $\alpha$ -amylase and thereby prevents the formation of D-glucose and ultimately the formation of NADPH as well.

#### Example 8: Medium for growing *S. glaucescens* GLA.O and producing acarbose

The fermentation was carried out, at 27°C on an orbital shaker at 120 rpm, in 500 ml Erlenmeyer flasks which were fitted with side baffles and which contained 100 ml of medium 2. The fermentation was terminated after 2 or 3 days. The pseudo-oligosaccharides were detected in a plate diffusion test as described in Example 9. No  $\alpha$ -amylase inhibitors were produced when medium 3 was used. This means that the production of the pseudo-oligosaccharides is inhibited by glucose. Other sugars, such as maltose and sucrose, or complex sugar sources (malt extract) can also come into consideration for producing pseudo-oligosaccharides using *S. glaucescens* GLA.O.

35

#### Medium 2:

Soybean flour      20 g/L

Starch                    20 g/L  
pH                        7.2

Medium 3:

5

Soybean flour          20 g/L  
Glucose                 20 g/L  
pH                        7.2

10    Example 9:    Biotest using *Mucor miehei*

15    A suspension of spores of the strain *Mucor miehei* was poured into agar (medium 5) ( $10^5$  spores/ml), and 10 ml of this mixture were in each case poured into Petri dishes. Paper test disks (6 mm diameter) were loaded  
20    with 10  $\mu$ l of acarbose [lacuna] (1 mg/ml) or with a sample from an *S. glaucescens* culture and laid on the test plates. The plates were then incubated at 37°C. Inhibition halos appeared on the starch-containing medium 5. A plate which was prepared with glucose (medium 4) instead of starch was used as a control. On this medium, no inhibition halo formed around the filter disks loaded with active compound.

Media 4 and 5:

	KH <sub>2</sub> PO <sub>4</sub> × 3 H <sub>2</sub> O	0.5	g
25	MgSO <sub>4</sub> × 7 H <sub>2</sub> O	0.2	g
	NaCl	0.1	g
	Ammonium sulfate	5	g
	Yeast nitrogen base	1.7	g
	Glucose (4) or starch (5)	5	g
30	Agar	15	g

Example 10: Transformation of *S. glaucescens* GLA.O

35    Protoplasts of the *Streptomyces glaucescens* strain were isolated as described in Motamedi and Hutchinson ((1987) PNAS USA 84: 4445-4449), and the isolated plasmid DNA was transferred into the cells by means of PEG transformation as explained in Hopwood et al. ((1985) Genetic manipulations of *Streptomyces*: a laboratory manual. The John



Innes Foundation, Norwich UK). The protoplasts were regenerated on R2YENG medium at 30°C (Motamedi and Hutchinson (1987) PNAS USA 84: 4445-4449). After 18 h, the agar plates were overlaid with a thiostrepton-containing solution and incubated at 30°C (final concentration  
5 of thiostrepton: 20 µg/ml).

Example 11: Isolation of the pseudo-oligosaccharides from *Streptomyces glaucescens* GLA.O, HPLC analysis and mass spectroscopy

#### 10 Isolation

The culture broth was separated from the mycelium by filtration. The culture filtrate which has been obtained in this way is then loaded onto an XAD16 column, after which the column is washed with water and the active  
15 components are eluted with 30% methanol. The eluate was concentrated down to the aqueous phase and the latter was extracted with ethyl acetate in order to remove lipophilic impurities. The aqueous phase was then concentrated and the active components were further purified in 5% methanol using a biogel P2 column. The individual fractions are collected  
20 in a fraction collector. The individual fractions were analyzed by means of the Mucor miehei biotest. Active eluates were rechromatographed, for further purification, in 5% methanol on biogel P2. The material which was isolated in this way was investigated by HPLC and MS.

#### 25 HPLC

Column: Nucleosil® 100 C-18

Eluent 0.1% phosphoric acid = A/acetonitrile = B

Gradient: from 0 to 100% B in 15 min

30 Detection: 215 nm

Flow 2 ml/min

Injection volume: 10-20 µl

Using HPLC, it was not possible to distinguish the pseudo-oligosaccharide  
35 preparation from *S. glaucescens* GLA.O from authentic acarbose. Both the retention time and the UV absorption spectrum of the two components were identical in this eluent system. The pseudo-oligosaccharide mixture was not fractionated under these conditions.

### Mass spectroscopic analysis (MS)

The molecular weights and the fragmentation pattern of authentic acarbose and the pseudo-oligosaccharides isolated from *Streptomyces glaucescens* GLA.O were determined by means of electrospray MS. Analysis of the acarbose which is commercially obtainable from Bayer (Glucobay) gave a mass peak at 645.5 (acarbose). The purified samples from *S. glaucescens* GLA.O contain a mixture of different pseudo-oligosaccharides whose sugar side chains are of different lengths: 969 (acarbose + 2 glucose units), 807 (acarbose + 1 glucose unit), 645 (corresponds to authentic acarbose). When acarbose and the compound which is isolated from *S. glaucescens* GLA.O and which has a molecular weight of 645 are fragmented, the same molecular fragments are formed, i.e.: 145 (4-amino-4,6-deoxyglucose), 303 (Acarviosin) and 465 (303 together with one glucose unit).

Actinoplanes sp. SE50 also produces a mixture of acarbose molecules having sugar side chains of different length (Truscheit (1984) VIIIth International Symposium on Medicinal Chemistry, Proc. Vol 1. Swedish Academy of Pharmaceutical Sciences, Stockholm, Sweden). The length of the sugar side chains can be influenced by the choice of the fermentation parameters and of the substrate in the nutrient solution.

### Example 12: Southern hybridization using Actinoplanes sp. SE50/110 (ATCC31044)

The chromosomal DNA was isolated from the strain Actinoplanes sp. SE50/100 and digested with restriction enzymes (PstI and BamHI). A Southern hybridization was then carried out using a probe which encompasses the coding region of the dTDP-glucose 4,6-dehydratase acbD from *Streptomyces glaucescens* GLA.O (fragment d, Fig. 3). The probe hybridizes with distinct bands from Actinoplanes sp. SE50/110 (Fig. 5, lanes 1 and 2). This provides the possibility of isolating the corresponding fragments from Actinoplanes sp. SE50/100 and other strain lines. Whether these DNA regions are in fact involved in the biosynthesis of acarbose remains to be demonstrated in subsequent investigations. Alternatively, the PCR primers 1 and 2 (Tab. 1) could also be used for amplifying the dTDP-glucose 4,6-dehydratase from Actinoplanes sp.

## Legends:

- 5      Fig. 1:      Southern hybridization using *S. glaucescens* GLA.O. Lane 1: PstI, lane 2: BamHI, lane 3: BglII. The labeled PCR fragment HstrE<sup>\*</sup> was used as the probe. Labeling of DNA fragments which are involved in the biosynthesis of hydroxystreptomycin.
- 10      Fig. 2:      Southern hybridization using *S. glaucescens* GLA.O. Lane 1: PstI, lane 2: BamHI, lane 3: BglII. The labeled PCR fragment acbD<sup>\*</sup> was used as the probe. Labeling of DNA fragments which are involved in the biosynthesis of the pseudo-oligosaccharides.
- 15      Fig. 3:      Restriction map of the 6.8 kb PstI fragment from *Streptomyces glaucescens* GLA.O. Open reading frames and the direction in which each is transcribed are indicated by arrows. The fragments a, b, c and d identify DNA regions which are explained in more detail in the text.
- 20      Fig. 4:      Southern hybridization using *Streptomyces glaucescens*  $\Delta$ acb: lane 1: PstI, lane 2: PstI/HindIII, and *Streptomyces glaucescens* GLA.O lane 3: PstI, lane 4: PstI/HindIII. The labeled 1.0 kb SstI fragment a (Fig. 3) was used as the probe.
- 25      Fig. 5:      Southern hybridization using *Actinoplanes* sp. SE50/100: lane 1: PstI, lane 2: BamHI and *Streptomyces glaucescens* GLA.O lane 3: PstI. The labeled 1.0 kb SmaI/EcoRI fragment d (dTDP-glucose 4,6-hydratase, Fig. 3) was used as the probe. The arrows indicate the labeled DNA fragments (BamHI: 2.1 and 0.7 kb, PstI: ~11-12 kb)
- 30      Tab. 4:      DNA sequence of the 6.8 kb PstI fragment from *Streptomyces glaucescens* GLA.O (SEQ ID NO.: 7). The deduced amino acid sequences (SEQ ID NO.: 8-13) of the identified open reading frames are given under the DNA
- 35

sequences. Start and stop codons and potential ribosome binding sites are underlined.

acbA: SEQ ID NO.: 8

acbB: SEQ ID NO.: 9

acbC: SEQ ID NO.: 10

acbD: SEQ ID NO.: 11

acbE: SEQ ID NO.: 12

acbF: SEQ ID NO.: 13

5

Variable	Mean	SD	Min	Max
Age	35.2	10.5	22	65
Gender	Male			
Marital status	Married			
Education	High school			
Occupation	Unemployed			
Religion	Islam			
Family size	4.5	1.2	2	8
Income	1500	500	500	3000
Health status	Good			
Smoking	Non-smoker			
Alcohol consumption	None			
Stress level	Low			
Social support	High			
Life satisfaction	High			
Resilience	High			
Optimism	High			
Self-efficacy	High			
Problem-solving	High			
Emotional stability	High			
Psychological well-being	High			
Life satisfaction	High			
Resilience	High			
Optimism	High			
Self-efficacy	High			
Problem-solving	High			
Emotional stability	High			
Psychological well-being	High			
Life satisfaction	High			
Resilience	High			
Optimism	High			
Self-efficacy	High			
Problem-solving	High			
Emotional stability	High			
Psychological well-being	High			
Life satisfaction	High			
Resilience	High			
Optimism	High			
Self-efficacy	High			
Problem-solving	High			
Emotional stability	High			
Psychological well-being	High			
Life satisfaction	High			
Resilience	High			
Optimism	High			
Self-efficacy	High			
Problem-solving	High			
Emotional stability	High			
Psychological well-being	High			
Life satisfaction	High			
Resilience	High			
Optimism	High			
Self-efficacy	High			
Problem-solving	High			
Emotional stability	High			
Psychological well-being	High			
Life satisfaction	High			
Resilience	High			
Optimism	High			
Self-efficacy	High			
Problem-solving	High			
Emotional stability	High			
Psychological well-being	High			
Life satisfaction	High			
Resilience	High			
Optimism	High			
Self-efficacy	High			
Problem-solving	High			
Emotional stability	High			
Psychological well-being	High			
Life satisfaction	High			
Resilience	High			
Optimism	High			
Self-efficacy	High			
Problem-solving	High			
Emotional stability	High			
Psychological well-being	High			
Life satisfaction	High			
Resilience	High			
Optimism	High			
Self-efficacy	High			
Problem-solving	High			
Emotional stability	High			
Psychological well-being	High			
Life satisfaction	High			
Resilience	High			
Optimism	High			
Self-efficacy	High			
Problem-solving	High			
Emotional stability	High			
Psychological well-being	High			
Life satisfaction	High			
Resilience	High			
Optimism	High			
Self-efficacy	High			
Problem-solving	High			
Emotional stability	High			
Psychological well-being	High			
Life satisfaction	High			
Resilience	High			
Optimism	High			
Self-efficacy	High			
Problem-solving	High			
Emotional stability	High			
Psychological well-being	High			
Life satisfaction	High			
Resilience	High			

**P  
B  
C  
I**

**S  
P  
h  
I**

К  
Р  
П  
Т

[illegible]

CAGGCCGGGCTCGGTTCCGGCCAGCCGGAACTCCTTGACGAGGTGTTCCGCCACGATCAC  
 GTCCGGCCCGAGCGCAAGCCGGTCCGCCTTGAGGAAGTCTCCACAAGCCGGTGCTAGTG 720

L G P E R E A L R F E K V L H E A V I V -  
acbA

GCGATCACCCGCTCGACGGCCGTCTCCAGCAGGCGCAGGCCCTCGTTCGAGCAGCGCCTCG  
 -----+-----+-----+-----+-----+-----+-----+ 780  
 CGCTAGTGGGCGAGCTGCCGGCAGAGGTCTCCGCGTCCGGGAGCAGCTCGTCGGGAGC  
 A I V R E V A T E L L R L G E D L L A E -

TCGAGGGTGAACGGCGGTGCCAGCCGCAGGATGTGGCCGCCAGGGAGGTGCGCAGCCCC  
+ + + + + 840  
AGCTCCCACTTGCCGCCACGGTCGGCGTCCTACACCGGCGGGTCCCTCCACGCGTCGGGG  
D L T F P P A L R L I H G G L S T R L G -

S  
M  
A  
I

AGGTCGAGGGCGGTGGTGTAGACGGCCCCGGGCGGTCTCGGGGGCGGGTGCCCCGGCCGACG  
-----+-----+-----+-----+-----+-----+-----+-----+-----+ 900  
TCCAGCTCCCGCCACCACATCTGCCGGGGCCCGCCAGAGCCCCCGCCACGGGCGGGCTGC  
L D L A T T Y V A R A T E P A P A R G V -

GCCTCGGTGACGAACCTCCAGGCCCCACAGCAGTCCGAGGCCGCTACCTGGCCGAGCTGG  
-----+-----+-----+-----+-----+ 960  
CGCAGCCACTGCTTGAGGTCCGGGGTGTCTCAGGCTCCGGCGCATGGACCGGCTCGACC  
A D T V F E L G W L L G L G R V Q G L Q -

S  
S  
t  
I

GGGAAGCGGGACTCCAGGGCGCGCAGCCGCTCCTGGATGAGCTCGCCGAGGACGCGCACG  
-----+-----+-----+-----+-----+-----+-----+-----+ 1020  
CCCTTCGCCCTGAGGTCCCGCGCGTGGCGAGGACCTACTCGAGCGGCTCCTGCGCGTGC  
P F R S E L A R L R E O I L E G L V R V -

CGGTCGATCAGCCGGTCGCGCTCGACGACCTCCAGCGTGGCGCGGGCGGCGCGATCCCC  
+-----+-----+-----+-----+-----+-----+-----+-----+ 1080  
GCCAGCTAGTCGGCCAGCGCGAGCTGCTGGAGGTGCGACCGCGCCCGCCGCGCTAGGGG  
R D I L R D R E V V E L T A R A A A I G -

S  
m  
a  
T

AGTGGGTTGCTCGCGTACGTCGAGGCGTACGCCCGGGGTGGCCGCCTCCGGCCTGCGCA  
 +-----+-----+-----+-----+-----+-----+-----+-----+ 1140  
 TCACCCAAACGAGCGCATGCAGCTCCGCATGCGGGGCCCCACCGGCGGAGGCCGGACGCGT  
 L P N S A Y T S A Y A G P H G G G A Q A -

GCTTCCGCGCGTCCGGCCAGACCGGCGAAGGGGAATCCGCTCGCGGTGCCCTTGGACAGC  
-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 1200  
CGAAGCGCGCAGGCCCGGTCTGTCGCCGCTTCCCCTTAGGCGAGCGCCACGGGAACCTGTCTG  
A E A R G A L V A F P F G S A T G K S L -  
ATCGCCAGGTCCGGCTCGATGCCGAACAGTTTCGCTGGCGAGGAAGGCGCCGGTGCGCCCCG  
-----+-----+-----+-----+-----+-----+-----+-----+-----+ 1260  
TAGCGGTCCAGGCCGAGCTACGGCTTGTCGAAGCGACCGCTCCTTCCGCGGCCACGCGGGC  
M A L D P E I G F L E S A L F A G T R G -  
CCGCGCGGTGAGGACCTCGTCGGCGACGAGCAGCACGCCCGCCGTCCCGGCAGGCGCCGGCG  
-----+-----+-----+-----+-----+-----+-----+-----+-----+ 1320  
GGCGGCCACTCCTGGAGCAGCCGCTGCTCGTCGTGCGGCGGCAGGGCCGTCCGCGGCCCGC  
G G T L V E D A V L L V G G D R C A G A -  
ATCCGCTCCCAGTAGCCGGGGGGCGGCACGATGACGCCTGCCGCGCCGAGGACGGGTTCG  
-----+-----+-----+-----+-----+-----+-----+-----+-----+ 1380  
TAGGCGAGGGTTCATCGGCCCGCCGCTGCTACTGCGGACGGCGCGGCTCCTGCCCAAGC  
I R E W Y G P P P V I V G A A G L V P E -  
AAGACCAGGGCCGAGACGTTGGGCTTCTCCGCGATGTGCCGGCGCACGAGGGTTCGCGCAC  
-----+-----+-----+-----+-----+-----+-----+-----+-----+ 1440  
TTCTGGTCCCGGCTCTGCAACCCGAAGAGGCGCTACACGGCCGCGTGTCTCCAGCGCGTG  
F V L A S V N P K E A I H R R V L T A C -  
CGCACGTGCGACGAGGGGTACTCCAGGCCCGAGGGGACAGCGGTAGCCAGTAGGGGCTGTA  
-----+-----+-----+-----+-----+-----+-----+-----+-----+ 1500  
GCGTGCAGCGTGTCTCCCATGAGGTCCGGGTCCCCTGTGCGCATCGGTTCATCCCGACAT  
R V D C S P Y E L G L P C R Y G T P A T -  
GCCAGCACGCTGTTGCCGCTGAAGGCCTGGTGGCCGATGTCCAGTGGACCAGCATCCGG  
-----+-----+-----+-----+-----+-----+-----+-----+-----+ 1560  
CGGTGCTGCGACAACGGCGACTTCCGGACCACCGGCTACAGGGTCACTTGGTGTAGGCC  
A L V S N G S F A Q H G I D W H V L M R -  
GCGCCCATGGTCTTGCCGCTGGAAGCCGTGGCGCAGGGCGCAGATCCGGTTCGCGCCCGGC  
-----+-----+-----+-----+-----+-----+-----+-----+-----+ 1620  
CGCGGGTACCAGAACGGCACCTTCGGCACCGCGTCCCGCGTCTAGGCCAACGCCGGGCCG  
A G M T K G H F G H R L A C I R N R G P -  
GCGGCGGTGCGCTGGACGACCCGACGGGCGGCCCTCGACCACCTCCGCGCCGGTGGAGAAG  
-----+-----+-----+-----+-----+-----+-----+-----+-----+ 1680  
CGCCGCCAGCGGACCTGCTGGGCGTCCCGCCGGAGCTGGTGGAGGCGCGGCCACCTCTTC  
A A T A Q V V R L A A E V V E A G T S F -  
AAGGCGTAGGTGTGAGCTGTTCCGGGCAGCAGCCTGGCGAGCAGTTCAGCAGGCCGGCG  
-----+-----+-----+-----+-----+-----+-----+-----+-----+ 1740  
TTCCGCATCCACAGCTCGACAAGCCCGTCTGTCGGACCGCTCGTCAAGGTCTGTCGGCCCGC  
F A Y T D L Q E P L L R A L L E L L G A -  
CGGTCCGGCGTGGCGCTGTCTGACGTTCCACAGGCGGCGGGCCTGGGTGGTGAAGTCC  
-----+-----+-----+-----+-----+-----+-----+-----+-----+ 1800  
GCCAGGCCCGACCGCGACAGCACCTGCAAGGTGTCCGCCGCCGACCCCACTCACGG  
R D P T A S D H V N W L R R A Q T T L A -  
TCGACGACCTCCGGGTGCCCGTGGCCAGTGACTGGGTGAGGGTCCCGGCCCGGAAGTCG  
-----+-----+-----+-----+-----+-----+-----+-----+-----+ 1860  
AGCTGCTGGAGGCCACGGGCACCGGGTCACTGACCCACTCCAGGGCGCGGCTTCAGC  
E V V E P H G H G L S O T L T G A A F D -

AGGTA CTGGTTGCCGTTCCAGGTCGGT CAGAACGGGACCGCGTCCCTCGGCGAAGACCCG  
-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 1920  
TCCATGACCAACGGCAGGTCCAGCCAGTCTTGCCCTGGCGCAGGGAGCCGCTTCTGGGGCC  
L Y Q N G D L D T L V P G R G E A F V R -  
CGTCCGTTGGACGGCTTCTCGGAGGGCGCCGGCGCCAGGTGGCGGGCCTCCCGTGCCAGG  
-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 1980  
GCAGGCACCTGCCGAAGGAGCCTCCGCGGGCGCGGTCCACCGCCCGGAGGGGCACGGTCC  
R G H V A E E S A G P A L H R A E R A L -  
TGCTGTGTCTGCCGTAAGCCTGT CATCGCTGCCTCTGCTCGTGGACCGGCTGACGCGAT  
-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 2040  
ACGACACAGACGGCATTCCGACAGTAGCGAGGAGCAGACAGCCTGGCCGACTGCGCTA  
H Q T Q R L G T M  
-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+  
CGCCGGCGAACTGCGTTGTGGCGCACCACGGTTGGGGCGGCTCGGCGCTGAGTCAAACAC  
-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 2100  
GCGGCCGCTTGACGCAACACCGGTGGTGCCAAACCCCGCGAGCCGCGACTCAGTTTGTG  
-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+  
TTGAACACACACCGCTGCAAGAGTTTGCGGGTTGTTTCAGAAAGTTGTTGCGAGCGGGCC  
-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 2160  
AACTTGTGTGTGGCGACGTTCTCAAACGCCCAACAAAGTCTTTCAACAACGCTCGCCGGG  
-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+  
CGGCACTCTGGTTGAGTCGACGTGCTTACCGCGCCACCACGCCTCACGTTGAGGAGGGA  
-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 2220  
GCCCTGAGACCAACTCAGCTGCACGAATGCCCGGGTGGTGCGGAGTGCAAGCTCCTCCCT  
-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+  
CCTGTGAGAACAAGCCCGCAGACCGACCCGCTCCCGCGGAGGCGAGGTGAAGGCCCTGG  
-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 2280  
GGACACTCTTGTTCGGGCGTCTGGCTGGGCGAGGGCGCCTCCGGCTCCACTTCCGGGACC  
-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+  
V K A L V -  
-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+  
acbC -----

P  
v  
u  
I  
I

TCCTGGCAGGTGGAACCGGCAGCAGACTGAGGCCGTTACCCACACCGCCGCCAAGCAGC  
-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 2340  
AGGACCGTCCACCTTGGCCGTCGTCGACTCCGGCAAGTGGGTGTGGCGGGCGGTTCTGTCG  
L A G G T G S R L R P F T H T A A K Q L -  
TGCTCCCCATCGCCAACAAGCCCGTGCTCTTCTACGCGCTGGAGTCCCTCGCCCGGGCGG  
-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 2400  
ACGAGGGGTAGCGGTTGTTTCGGGCACGAGAAGATGCGCGACCTCAGGGAGCGGCGCCGCC  
L P I A N K P V L F Y A L E S L A A A G -  
GTGTCCGGGAGGCCGGCGTCTGTCGTTGGGCGCGTACGGCCGGGAGATCCGCGAACTCACCG  
-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 2460  
CACAGGCCCTCCGGCCGCAGCAGCACCCGCGCATCCGGCCCTCTAGGCGCTTGAGTGGC  
V R E A G V V V G A Y G R E I R E L T G -  
GCGACGGCACCGCGTTCCGGTTACGCATCACCTACCTCCACCAGCCCCGCGCGCTCGGTC  
-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 2520  
CGCTGCCGTGGCGCAAGCCCAATGCGTAGTGGATGGAGGTGGTTCGGGGCGGGCGAGCCAG  
D G T A F G L R I T Y L H Q P R P L G L -  
TCGCGCACGCGGTGCGCATCGCCCGCGGCTTCTGGGCGACGACGACTTCTGCTGTACC  
-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 2580  
AGCGCGTGCGCCACCGGTAGCGGGCGCCGAAGGACCCGCTGCTGCTGAAGGACGACATGG  
A H A V R I A R G F L G D D D F L L Y L -



TGGGGGACAACTACCTGCCCCAGGGCGTCACCGACTTCGCCCCCAATCGGCCGCCGATC  
-----+-----+-----+-----+-----+ 2640  
ACCCCTGTGATGGACGGGGTCCCGCAGTGGCTGAAGCGGGCGGTTAGCCGGCGGCTAG  
G D N Y L P Q G V T D F A R Q S A A D P -  
CCGCGGCGGCGCGGCTGCTGCTCACCCCGGTGCGGGACCGGTCCGCCTTCGGCGTGGCGG  
-----+-----+-----+-----+-----+ 2700  
GGCGCGCGCGGGCGGACGACGAGTGGGGCCAGCGCCTGGGCAGGCGGAAGCCGAGCGCC  
A A A R L L L T P V A D P S A F G V A E -  
AGGTCGACGCGGACGGGAACGTGCTGCGCTTGGAGGAGAAACCCGACGTCCCGCGCAGCT  
-----+-----+-----+-----+-----+ 2760  
TCCAGCTGCGCCTGCCCTTGACGACGCGAACCTCCTCTTTGGGCTGCAGGGCGCGCTCGA  
V D A D G N V L R L E E K P D V P R S S -  
CGCTCGCGCTCATCGGCGGTACGCCTTCAGCCCGGCGGTCCACGAGGCGGTACGGGCCA  
-----+-----+-----+-----+-----+ 2820  
GCGAGCGGAGTAGCCGACATGCGGAAGTCGGGCGGGCAGGTGCTCCGCCATGCCCGGT  
L A L I G V Y A F S P A V H E A V R A I -  
TCACCCCTCCGCCCCGCGCGAGCTGGAGATCACCCACGCGGTGCAGTGGATGATCGACC  
-----+-----+-----+-----+-----+ 2880  
AGTGGGGGAGGCGGGCGCGCTCGACCTCTAGTGGGTGCGGCACGTACCTACTAGCTGG  
T P S A R G E L E I T H A V Q W M I D R -  
GGGGCCTGCGGTACGGGCGGAGACCACCACCGGCCCTGGCGGACACCGGCAGCGCGG  
-----+-----+-----+-----+-----+ 2940  
CCCCGAGCGGCATGCCCGGCTCTGGTGGTGGGCGGGACCGCGCTGTGGCCGTGCGGCC  
G L R V R A E T T T R P W R D T G S A E -  
AGGACATGCTGGAGGTCAACCGTCACGTCTCGGACGGACTGGAGGGCCGCATCGAGGGGA  
-----+-----+-----+-----+-----+ 3000  
TCCTGTACGACCTCCAGTTGCGAGTGCAGGACCTGCCTGACCTCCCGCGGTAGCTCCCT  
D M L E V N R H V L D G L E G R I E G K -  
AGGTCGACGCGCACAGCAGCTGGTCCGCCCGGTCGGGTGGCCGAAGGCGCGATCGTGC  
-----+-----+-----+-----+-----+ 3060  
TCCAGCTGCGCGTGTCTGCGACCGAGCCGGCCAGGCCACCGCTTCGCGCTAGCACG  
V D A H S T L V G R V R V A E G A I V R -  
GGGGGTACACGTGCTGGGCCCCGTGCTGATCGGCGCGGTGCCGTGCTCAGCAACTCCA  
-----+-----+-----+-----+-----+ 3120  
CCCCAGTGTGCACACCGGGGCCACCTAGCCCGCCCCACGGCAGCAGTCGTTGAGGT  
G S H V V G P V V I G A G A V V S N S S -  
GTGTGCGCCCGTACACCTCCATCGGGGAGGACTGCCGGTTCGAGGACAGCGCCATCGAGT  
-----+-----+-----+-----+-----+ 3180  
CACAGCCGGGCATGTGGAGGTAGCCCCCTCCTGACGGCCAGCTCCTGTGCGGGTAGCTCA  
V G P Y T S I G E D C R V E D S A I E Y -  
ACTCCGTCTGCTGCGCGGCGCCAGGTGAGGGGGCGTCCCGCATCGAGGCGTCCCTCA  
-----+-----+-----+-----+-----+ 3240  
TGAGGCAGGACGACGCGCGGGTCCAGCTCCCCCGCAGGGCGTAGCTCCGCAGGGAGT  
S V L L R G A Q V E G A S R I E A S L I -  
TCGGCCGCGGCGCGCTGCTGCGGCGGGCCCCCGTCTCCCGCAGGCTCACCGACTGGTGA  
-----+-----+-----+-----+-----+ 3300  
AGCCCGCGCGCGGCGAGCAGCGGGCGGGGGGCGAGGGCGTCCGAGTGGCTGACCACT  
G R G A V V G P A P R L P Q A H R L V I -

092353-0004

G D H S K V Y L T P \* M T T T I L V T G G -  
acbd \_\_\_\_\_

S  
m  
a  
I

AGCGGGCTTCATTGCTCCGCCTACGTCCGCCGGCTCCTGTGCGCCGGGGCCCCCGGCGG  
-----+-----+-----+-----+-----+ 3420  
TCGCCCCGAAGTAAGCGAGGCGGATGCAGGCGGCCGAGGACAGCGGGCCCCGGGGGCGCGC  
A G F I R S A Y V R R L L S P G A P G G -

CGTCGCGGTGACCGTCTCGACAACTCACCTACGCCGGCAGCGCTCGCCCCGCTGCACGC  
-----+-----+-----+-----+-----+ 3480  
GCAGCGCCACTGGCAGGAGCTGTTTGAGTGGATGCGGCCGTGCGAGCGGGCGGACGTGCG  
V A V T V L D K L T Y A G S L A R L H A -

GGTGCGTGACCATCCCCGGCCTCACCTTCGTCCAGGGCGACGTGTGCGACACCGCGCTCGT  
-----+-----+-----+-----+-----+ 3540  
CCACGCACTGGTAGGGCCGGAGTGGAAGCAGGTCCCGCTGCACACGCTGTGGCGCGAGCA  
V R D H P G L T F V Q G D V C D T A L V -

CGACACGCTGGCCGCGCGGCACGACGACATCGTGCACCTTCGCGGCCGAGTCGCACGTGCA  
-----+-----+-----+-----+-----+ 3600  
GCTGTGCGACCGGCGCGCCGTGCTGCTGTAGCACGTGAAGCGCCGGCTCAGCGTGCAGCT  
D T L A A R H D D I V H F A A E S H V D -

CCGCTCCATCACCGACAGCGGTGCCTTCACCCGCACCAACGTGCTGGGCACCCAGGTCCT  
-----+-----+-----+-----+-----+ 3660  
GGCGAGGTAGTGGCTGTGCGCCACGGAAGTGGGCGTGTTGCACGACCCGTGGGTCCAGGA  
R S I T D S G A F T R T N V L G T Q V L -

GCTCGACGCGCGCTCCGCCACGGTGTGCGCACCTTCGTGCACGTCTCCACCGACGAGGT  
-----+-----+-----+-----+-----+ 3720  
CGAGCTGCGGCGCGAGGCGGTGCCACACGCGTGGAAGCACGTGCAGAGGTGGCTGCTCCA  
L D A A L R H G V R T F V H V S T D E V -

GTACGGCTCCCTCCCCGCACGGGGCCGCCGCGGAGAGCGACCCCTGCTTCCGACCTCGCC  
-----+-----+-----+-----+-----+ 3780  
CATGCCGAGGGAGGGCGTGCCCGGGCGGCGCTCTCGCTGGGGGACGAAGGCTGGAGCGG  
Y G S L P H G A A A E S D P L L P T S P -

GTACGCGCGCTCGAAGGCGGCCTCGGACCTCATGGCGCTCGCCACCACCGCACCCACGG  
-----+-----+-----+-----+-----+ 3840  
CATGCGCGCGACGCTTCCGCCGGAGCCTGGAGTACCGCGAGCGGGTGGTGGCGTGGGTGCC  
Y A A S K A A S D L M A L A H H R T H G -

CCTGGACGTCCGGGTGACCGCTGTTTCGAACAACCTTCGGCCCCCACCAGCATCCCAGAA  
-----+-----+-----+-----+-----+ 3900  
GGACCTGCAGGCCCCACTGGGCGACAAGCTTGTTGAAGCCGGGGGTGGTCCTAGGGCTCTT  
L D V R V T R C S N N F G P H Q H P E K -

GCTCATACCGCGCTTCCGTGACCAGCCTCCTGTCCGGCGGCACCGTTCCTCTACGGCGA  
-----+-----+-----+-----+-----+ 3960  
CGAGTATGGCGCGAAGGACTGGTGGAGGACAGGCCCGCGTGGCAAGGGGAGATGCCGCT  
L I P R F L T S L L S G G T V P L Y G D -

GGTCTATACCGCGCTTCCTGACCAGCCTCCTGTCCGGCGGCACCGTTCCCCTCTACGGCGA  
 -----+-----+-----+-----+-----+-----+-----+-----+ 3960  
 CGAGTATGGCGCGAAGGACTGGTCCGAGGACAGGCCCGCGCTGGCAAGGGGAGATGCCGCT  
 L I P R F L T S L L S G G T V P L Y G D -

[illegible]

CCGCGTGTCTGGGCGGCGGGAGAGATCTACAACATCGGGGGCGGCACCTCGCTGCCCAA  
-----+-----+-----+-----+-----+ 4080  
GGCGCACAGCCCGGCGGCCCTCTCTAGATGTTGTAGCCCCCGCCGTGGAGCGACGGGTT  
R V S G R P G E I Y N I G G G T S L P N -

**S  
S  
C  
I**

CCTGGAGCTCACGCACCGTTGCTCGCACTGTGCGGCGCGGGCCCGGAGCGCATCGTCCA  
 -----+-----+-----+-----+-----+-----+-----+ 4140  
 GGACCTCGAGTGCCTGGCCAACGAGCGTGACACGCCGCGCCCGGGCCTCGCGTAGCAGGT  
 L E L T H R L L A L C G A G P E R I V H -

CGTCGAGAACCGCAAGGGGCACGACCGGCGCTACGCGGTCGACCACAGCAAGATCACCGC  
-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 4200  
GCAGCTCTTGGCGTTCCCGTGCTGGCCGCGATGCCAGCTGGTGTCTTCTAGTGGCG  
V E N R K G H D R R Y A V D H S K I T A -

**N  
R  
U  
I**

GGAACTCGGTTACCGGCCGCGCACCGACTTCGCGACCGCGCTGGCCGACACCGCGAAGTG  
-----+-----+-----+-----+-----+-----+-----+-----+-----+ 4260  
CCTTGAGCCAATGGCCGGCGCGTGGCTGAAGCGCTGGCGCGACCGGCTGTGGCGCTTCAC  
E L G Y R P R T D F A T A L A D T A K W -

GTACGAGCGGCACGAGGACTGGTGGCGTCCCCTGCTCGCCGCGACATGACGTCGGGGCCGG  
+-----+-----+-----+-----+-----+-----+-----+-----+ 4320  
CATGCTCGCCGTGCTCCTGACCACCGCAGGGGACGAGCGGCGCTGTACTGCAGCCCGGCC  
Y E R H E D W W R P L L A A T \*

ACCGCAACCACCGGCCCGGCCGGCACACCGCCGCCCGCGCCGGTGGCCGGCCGGTCAG  
-----+-----+-----+-----+-----+-----+-----+-----+ 4380  
TGGCGTTGGTGGCCGGGGCCGGCCGTGTGGCGCGCGGCCCGGCCACCGGCCGGCCAGTC

CGTCCGTGAGCCGGGCGCCGGCCGCCCGCGGGCCGGCGGGTGGACCCCGGACCACC  
-----+-----+-----+-----+-----+-----+-----+ 4440  
GCAGGCACTCGGCCCGGGCCGGCGGGGCGCCCGGCCGCCACCTGGGGGCGGTGG  
R G H A P R R G G R P G A A T S G R V V -

E  
C  
O  
R  
I

AGTTCGGGCATGAAGACGAATTCGGTGCGCGGGCGGCGTTCGGCTCATCTCCTCCAGC  
-----+-----+-----+-----+-----+ 4500  
TCAAGGCCGTA CTTCTGCTTAAGCCACGCGCCGCCGCCGCAAGGCGAGTAGAGGAGGTCTCG  
L E P M F V F E T R P P P T G S M E E L -

**S  
S  
T  
I**

**S  
m  
a  
I**

TCCGTGAGTTCGTCCTCGGTCGAGCCGCCCGGGGTCTGCGTGGCGAGCACGGGCGTGTA  
-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 5160  
AGGCACTCAAGCAGGAGCCAGCTCGGCGGGCCCCAGACGCACCGCTCGTGCCCGCACATC  
E T L E D E T S G G P T Q T A L V P T Y -

CCCTGACGCGTGAGCGCCTGCCCATCACCTGGGCCAGTGCGGGGAAGAAGGGGTGTCC  
-----+-----+-----+-----+-----+-----+-----+ 5220  
GGGACTGCGCACTCGCGGACGGGGTAGTGGACCCGGTCACGCCCCTTCTTCCCAACAGG  
G O R T L A O G M V O A L A P E E P N D -

AGTTCGGGGGTGACCAGTCCGACCAGCTCGGCGCGGCGCTGTGCGCGCCGGCTGCTCGTAG  
-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 5280  
TCAAGCCCCCACTGGTCAGGCTGGTCGAGCCGCGCCGCGACAGCGCGGCCGACGAGCATC  
L E P T V L G V L E A R R O R A P Q E Y -

CCACGCGCGTCCAGTGCGGTGAGCACCGAGTCGCGGGTGCCGGTGGCCACACCGCGCGCA  
-----+-----+-----+-----+-----+ 5340  
GGGTGCGCGAGGTCAGGCCAGTCGTGGCTCAGCGCCACGGCCACCGGTGTGGCGCGCGT  
G L A D L A T L V S D R T G T A V G R A -

**S  
m  
a  
I**

CGGTTACAGCACCCGGGCTGACCGTGGCCTTGCTGACGCCCGCCCGGGGCTGCGATGTCGGCG  
-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 5400  
GGCAAGTCGTGGGCCGACTGGCACCCGGAACGACTGCGGGCGGGCCCCGACGCTACAGCCGC  
G N L V R S V T A K S V G A R A A I D A -

AGCCGCATGGTCATGGCAACGCACCTCTACCTGTCGGGGCGTCAGGGCGTGCCACCGCGC  
-----+-----+-----+-----+-----+-----+-----+-----+-----+ 5460  
TCGGCGTACCAGTACCGTTGCGTGAGATGGACAGCCCCGCAGTCCCGCACGGGTGGCGCG  
L R M T M

**acbE**

GCGGAACCGGCGACTGCGGGGCACGGCCCGTCCGCCGCCACGGACCAGCGCCCCGAAA  
-----+-----+-----+-----+-----+-----+-----+ 5520  
CGCCTTGCGCGCCTGACGCCCCGTGCCGGGCAGCGGGCGGGTGCCTGGTGC CGCGGGCTTT

CGATGGCTGAAAATGCTTGCAGCAAATTGCCGCAACGTCTTTGCGCGGCTTTTCGATCCT  
-----+-----+-----+-----+-----+-----+-----+-----+ 5580  
GCTACCGACTTTTACGAACGTCGTTTAACGGCGTTGCAGAAAGCCGCCGAAAAGCTAGGA

GTTACGTTCTCTGGCAACCCCGGCGCGCAGAAACGGTTGGCGTGAGGCGTCCAGACCT  
 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 5640  
 CAATGCAAGGACCGTTGGGGCCGCGGCGCGTCTTTCGCCAACCGCACTCCGCAGGTCTGGA

CCGCCCCGATTCCGGGATCACTCAGGGGAGTTACAATGCGGCGTGGCATTGCGGCCACCG  
-----+-----+-----+-----+-----+ 5700  
GGCGGGCTAAGGCCCTAGTGAGTCCCCCTCAAGTGTTACGCCGCACCGTAACGCCGGTGGC  
M R R G I A A T A -

**acbF**

CGCTGTTTCGCGGCTGTGGCCATGACGGCATCGGCGTGTGGCGGGGGCGACAACGGCGGAA  
+ + + + + 5760  
GCGACAAGCGCCGACACCGGTACTGCCGTAGCCGCACACCGCCCCCGCTGTTGCCGCGCTT  
L F A A V A M T A S A C G G G D N G G S -

К  
Р  
Н  
І

CGCGTACCGACGCGGGCGGCACGGAGCTGTGCGGGACCGTCACCTTCTGGGACACGTCCA  
-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 5820  
CGCCATGGCTGCGCCCCGCCGTGCCTCGACAGCCCCCTGGCAGTGGAAGACCCTGTGCAGGT  
G T D A G G T E L S G T V T F W D T S N -

ACGGAAGCCGAGAAGGCCAGCTACCAGAGCCCTCGCGGAGGGCTTCGAGAAGGAGCACCAGCA  
-----+-----+-----+-----+-----+ 5880

TGCTTCGGCTCTTCCGCTGCATGGTCCGGGAGCGCCTCCCAGAGCTCTTCTCTCGTGGGCT  
E A E K A T Y Q A L A E G F E K E H P K -

AGGTTCGACGTCAAGTACGTCAACGTCCCCGTTCCGGCGAGGCGAACGCCAAGTTCAGAAGCG  
-----+-----+-----+-----+-----+ 5940

TCCAGCTGCAGTTCATGCAGTTGCAGGGCAAGCCGCTCCGCTTGCGGTTCAAGTTCCTTGC  
V D V K Y V N V P F G E A N A K F K N A -

CCGCGGGGCGGCAACTCCGGTGCCCCCGACGTGATGCGGTACGGAGGTGCGCTGGGTGCGGG  
-----+-----+-----+-----+-----+ 6000

GCGCGCCCGCGGTTGAGGCCACGGGGCCTGCACTACGCATGCCTCCAGCGGACCCAGCGCC  
A G G N S G A P D V M R T E V A W V A D -

ACTTCGCCAGCATCGGCTACCTCGCCCCGCTCGACGGCACGCCCGCCCTCGACGACGGGT  
-----+-----+-----+-----+-----+ 6060

TGAAGCGGTCTAGCCGATGGAGCGGGCGAGCTGCCGTGCGGGCGGGAGCTGCTGCCCA  
F A S I G Y L A P L D G T P A L D D G S -

CGGACCACCTTCCCCAGGGCGGCAGCACCAGGTACGAGGGGAAGACCTACGCGGTCCCCG  
-----+-----+-----+-----+-----+ 6120

GCCTGGTGGAAGGGGTCCCGCCGCTCGTGGTCCATGCTCCCCTTCTGGATGCGCCAGGGCG  
D H L P Q G G S T R Y E G K T Y A V P Q -

AGGTGATCGACACCCTGGCGCTCTTCTACAACAAGGAAGTCTGACGAAGGCCGGTGTCTG  
-----+-----+-----+-----+-----+ 6180

TCCAAGCTGTGGGACCGCGAGAAGATGTTGTTCTTGCAGACTGCTTCCGGCCACAGC  
V I D T L A L F Y N K E L L T K A G V E -

AGGTGCCGGGCTCCCTCGCCGAGCTGAAGACGGCCGCCCGGAGATCACCGAGAAGACCG  
-----+-----+-----+-----+-----+ 6240

TCCACGGCCCGAGGGAGCGGCTCGACTTCTGCCGGCGGGCGGCTCTAGTGGCTCTTCTGGC  
V P G S L A E L K T A A A E I T E K T G -

GCGCGAGCGGCCTCTACTGCGGGCGACGACCCGTAATTGGTTCTTGCCTACCTCTACG  
-----+-----+-----+-----+-----+ 6300

CGCGCTCGCCGAGATGACGCCCCGCTGCTGGGCATGAACCAAGGACGGGATGGAGATGC  
A S G L Y C G A T T R T W F L P Y L Y G -

GGGAGGGCGGGCGACCTGGTTCGACGAGAAGAACAAGACCGTCACGGTCGACGACGAAGCCG  
-----+-----+-----+-----+-----+ 6360

CCCTCCCGCCGCTGGACCAGCTGCTCTTCTTGTCTTGGCAGTGCCAGCTGCTGCTTCGGC  
E G G D L V D E K N K T V T V D D E A G -

GTGTGCGCGCCTACCGCGTCATCAAGGACCTCGTGGACAGCAAGGCGGCCATCACCGACG  
-----+-----+-----+-----+-----+ 6420

CACACGCGCGGATGGCGCAGTAGTTCCTGGAGCACCTGTGCTTCCGCCGGTAGTGGCTGC  
V R A Y R V I K D L V D S K A A I T D A -

CGTCCGACGGCTGGAACAACATGCAGAACGCCCTCAAGTCGGGCAAGGTCGCCATGATGG  
-----+-----+-----+-----+-----+ 6480

GCAGGCTGCCGACCTTGTGTACGTCTTGCAGAACTTCAGCCCGTTCAGCGGTAATAACC  
S D G W N N M Q N A F K S G K V A M M V -

TCAACGGCCCCCTGGGCCATCGAGGACGTCAAGGCGGGAGCCCCGCTTCAAGGACGCCGGCA  
-----+-----+-----+-----+-----+ 6540

AGTTGCCGGGGGACCCGGTAGCTCCTGCAGTTCGCCCTCGGGCGAAGTTCCTGCGGCCGT  
N G P W A I E D V K A G A R F K D A G N -

ACCTGGGGGTGCCCCCGTCCCGGCCGGCAGTGCCGGACAGGGCTCTCCCCAGGGCGGGT  
-----+-----+-----+-----+-----+ 6600  
TGGACCCCCAGCGGGGCGGGCCGGCCGTACGGCCTGTCCCGAGAGGGGTCCCGCCCA  
L G V A P V P A G S A G Q G S P Q S G W -

GGAACCTCTCGGTGTACGCGGGCTCGAAGAACCTCGACGCCTCTACGCCTTCGTGAAGT  
-----+-----+-----+-----+-----+ 6660  
CCTTGGAGAGCCACATGCGCCCGAGCTTCTTGGAGCTGCGGAGGATGCGGAAGCACTTCA  
N L S V Y A G S K N L D A S Y A F V K Y -

S

s

t

I

ACATGAGCTCCGCCAAGGTGCAGCAGCAGACCACCGAGAAGCTGAGCCTGCTGCCACCC  
-----+-----+-----+-----+-----+ 6720  
TGTACTCGAGGCGGTTCCACGTCGTCGTCTGGTGGCTCTTCGACTCGGACGACGGGTGGG  
M S S A K V Q Q Q T T E K L S L L P T R -

GCACGTCCGTCTACGAGGTCCCGTCCGTGCGGACAACGAGATGGTGAAGTTCTTCAAGC  
-----+-----+-----+-----+-----+ 6780  
CGTGCAGGCAGATGCTCCAGGGCAGGCAGCGCCTGTTGCTCTACCACTTCAAGAAGTTTCG  
T S V Y E V P S V A D N E M V K F F K P -

CGGCCGTGACAAGGCCGTGGAACGGCCGTGGATCGCCGAGGGCAATGCCCTCTTCGAGC  
-----+-----+-----+-----+-----+ 6840  
GCCGGCAGCTGTTCCGGCAGCTTGCCGGCACCTAGCGGCTCCCGTTACGGGAGAAGCTCG  
A V D K A V E R P W I A E G N A L F E P -

P

s

t

I

CGATCCGGCTGCAG  
-----+----- 6854  
GCTAGGCCGACGTC  
I R L Q -

T04080" E8922660



## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

- 5 (i) APPLICANT:
- (A) NAME: Hoechst Aktiengesellschaft
  - (B) STREET:
  - (C) CITY: Frankfurt
  - (D) FEDERAL STATE: -
  - 10 (E) COUNTRY: Germany
  - (F) POSTAL CODE: 65926
  - (G) TELEPHONE: 069-305-3005
  - (H) TELEFAX: 069-35-7175
  - (I) TELEX: -
- 15 (ii) TITLE OF APPLICATION: Isolation of the genes for  
biosynthesizing pseudo-oligosaccharides from  
Streptomyces glaucescens GLA.O and their use
- 20 (iii) NUMBER OF SEQUENCES: 13
- (iv) COMPUTER READABLE FORM:
- (A) MEDIUM TYPE: floppy disk
  - (B) COMPUTER: IBM PC compatible
  - 25 (C) OPERATING SYSTEM: PC-DOS/MS-DOS
  - (D) SOFTWARE: PatentIn Release #1.0, Version  
#1.25 (EPO)
- (2) INFORMATION FOR SEQ ID NO.: 1:
- 30 (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 22 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - 35 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA

## (ix) FEATURES:

(A) NAME/KEY: exon

(B) LOCATION: 1..22

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO.: 1:

CSGGSGSSGC SGGSTTCATS GG

22

## (2) INFORMATION FOR SEQ ID NO.: 2:

10

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 24 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

15

(D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA

## (ix) FEATURES:

20

(A) NAME/KEY: exon

(B) LOCATION: 1..24

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO.: 2:

25

GGGWVCTGGY VSGGSCCGTA GTTG

24

## (2) INFORMATION FOR SEQ ID NO.: 3:

30

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 546 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

35

## (ii) MOLECULE TYPE: DNA (genomic)

## (ix) FEATURES:

(A) NAME/KEY: exon

## (B) LOCATION: 1..546

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO.: 3:

(xi) SEQUENZBESCHREIBUNG: SEQ ID NO: 3:

CCCCGGGCGGG	GCGGGGTTCA	TCGGCTCCGC	CTACGTCCGC	CGGCTCCTGT	CGCCCGGGGC	60
CCCCGGGCGGC	GTCGCGGTGA	CCGTCTCTGA	CAAACTCACC	TACGCCGGCA	GCCTCGCCCG	120
CCTGCACGCG	GTGCGTGACC	ATCCCGGCCT	CACCTTCGTC	CAGGGCGACG	TGTGCGACAC	180
CGCGCTCGTC	GACACGCTGG	CCGCGCGGCA	CGACGACATC	GTGCACTTCG	CGGCCGAGTC	240
GCACGTCGAC	CGCTCCATCA	CCGACAGCGG	TGCCTTCACC	CGCACCACG	TGCTGGGCAC	300
CCAGGTCCTG	CTCGACGCCG	CGCTCCGCCA	CGGTGTGCGC	ACCCTCGTGC	ACGTCTCCAC	360
CGACGAGGTG	TACGGCTCCC	TCCCGCACGG	GGCCGCCGCG	GAGAGCGACC	CCCTGCTCCC	420
GACCTCGCCG	TACGCGGCGT	CGAAGGCGGC	CTCGGACCTC	ATGGCGCTCG	CCCACCACCG	480
CACCCACGGC	CTGGACGTCC	GGGTGACCCG	CTGTTGGAAC	AACTACGGCC	CGCACCAGTT	540
CCCCGGG						546

## 5 (2) INFORMATION FOR SEQ ID NO.: 4:

## (i) SEQUENCE CHARACTERISTICS:

- 10 (A) LENGTH: 541 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA (genomic)

## 15 (ix) FEATURES:

- (A) NAME/KEY: exon  
(B) LOCATION: 1..541

(xi) SEQUENZBESCHREIBUNG: SEQ ID NO: 4:

CCCCGGGTGC	TGGTAGGGGC	CGTAGTTGTT	GGAGCAGCGG	GTGATGCGCA	CGTCCAGGCC	60
GTGGCTGACC	TGCATGGCCA	GCGCGAGCAG	GTCGCCCCGAC	GCCTTGGAGG	TGGCATAGGG	120
GCTGTTGGGG	CGCAGCGGCT	CGTCCTCCGT	CCACGACCCC	GTCTCCAGCG	AGCCGTAGAC	180
CTCGTCGGTG	GACACCTGCA	CGAAGGGGGC	CACGCCGTGC	CGCAGGGCCG	CGTCGAGGAG	240
TGTCTGCGTG	CCGCCGGCGT	TGGTCCGCAC	GAACGCGGCG	GCATCGAGCA	GCGAGCGGTC	300



Ala Ala Gly Phe Met Gly Ser His Tyr Val Arg Thr Leu Leu Gly Pro  
 1 5 10 15  
 Asp Gly Pro Pro Asp Ala Val Val Thr Val Leu Asp Ala Leu Ser Tyr  
 20 25 30  
 Ala Gly Asn Leu Ala Asn Leu Asp Pro Val Arg Asp His Pro Arg Leu  
 35 40 45  
 Arg Phe Val His Gly Asp Ile Cys Asp Ala Asp Leu Val Asp Arg Val  
 50 55 60  
 Met Ala Gly Gln Asp Gln Val Val His Leu Ala Ala Glu Ser His Val  
 65 70 75 80  
 Asp Arg Ser Leu Leu Asp Ala Ala Ala Phe Val Arg Thr Asn Ala Gly  
 85 90 95  
 Gly Thr Gln Thr Leu Leu Asp Ala Ala Leu Arg His Gly Val Ala Pro  
 100 105 110  
 Phe Val Gln Val Ser Thr Asp Glu Val Tyr Gly Ser Leu Glu Thr Gly  
 115 120 125  
 Ser Trp Thr Glu Asp Glu Pro Leu Arg Pro Asn Ser Pro Tyr Ala Thr  
 130 135 140  
 Ser Lys Ala Ser Gly Asp Leu Leu Ala Leu Ala Met His Val Ser His  
 145 150 155 160  
 Gly Leu Asp Val Arg Ile Thr Arg Cys Ser Asn Asn Tyr Gly Pro Tyr  
 165 170 175  
 Gln His Pro Gly  
 180

(2) INFORMATION FOR SEQ ID NO.: 6:

(i) SEQUENCE CHARACTERISTICS:

- 5
- (A) LENGTH: 181 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: protein

(ix) FEATURES:

- (A) NAME/KEY: PCR acbD.Pep
- (B) LOCATION: 1..181

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO.: 6:

009255-1007

Pro Gly Gly Ala Gly Phe Ile Gly Ser Ala Tyr Val Arg Arg Leu Leu  
 1 5 10 15  
 Ser Pro Gly Ala Pro Gly Gly Val Ala Val Thr Val Leu Asp Lys Leu  
 20 25 30  
 Thr Tyr Ala Gly Ser Leu Ala Arg Leu His Ala Val Arg Asp His Pro  
 35 40 45  
 Gly Leu Thr Phe Val Gln Gly Asp Val Cys Asp Thr Ala Leu Val Asp  
 50 55 60  
 Thr Leu Ala Ala Arg His Asp Asp Ile Val His Phe Ala Ala Glu Ser  
 65 70 75 80  
 His Val Asp Arg Ser Ile Thr Asp Ser Gly Ala Phe Thr Arg Thr Asn  
 85 90 95  
 Val Leu Gly Thr Gln Val Leu Leu Asp Ala Ala Leu Arg His Gly Val  
 100 105 110  
 Arg Thr Leu Val His Val Ser Thr Asp Glu Val Tyr Gly Ser Leu Pro  
 115 120 125  
 His Gly Ala Ala Ala Glu Ser Asp Pro Leu Leu Pro Thr Ser Pro Tyr  
 130 135 140  
 Ala Ala Ser Lys Ala Ala Ser Asp Leu Met Ala Leu Ala His His Arg  
 145 150 155 160  
 Thr His Gly Leu Asp Val Arg Val Thr Arg Cys Ser Asn Asn Tyr Gly  
 165 170 175  
 Pro His Gln Phe Pro  
 180

(2) INFORMATION FOR SEQ ID NO.: 7:

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 6854 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: double  
 (D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURES:

- (A) NAME/KEY: "acarbose" biosynthesis gene cluster  
 (B) LOCATION: 1..6854

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO.: 7:

[illegible]

TCGACGACCT CCGGGTGCCC GTGGCCAGT GACTGGGTGA GGGTCCCGGC CGCGAAGTCG 1860  
 AGGTACTGGT TGCCGTCCAG GTCGGTCAGA ACGGGACCGC GTCCCTCGGC GAAGACCCGG 1920  
 CGTCCGTGGA CGGCTTCCTC GGAGGGCCCC GGGCCAGGT GGGGGGCTC CCGTGCCAGG 1980  
 TGCTGTGTCT GCCGTAAGCC TGTCATCGCT GCCTCTGCTC GTCGGACCGG CTGACGCGAT 2040  
 CGCCGGCGAA CTGCGTTGTG GCGCACCACG GTTGGGGCGG CTCGGCGCTG AGTCAAACAC 2100  
 TTGAACACAC ACCGCTGCAA GAGTTTGGG GTTGTTCAG AAAGTTGTTG CGAGCGGCCC 2160  
 CGGCACTCTG GTTGAGTCGA CGTGCTTACG GCGCCACCAC GCCTCACGTT CGAGGAGGGA 2220  
 CCTGTGAGAA CAAGCCCGCA GACCGACCGG CTCCCGCGGA GCGCGAGGTG AAGGCCCTGG 2280  
 TCCTGGCAGG TGGAAACCGC AGCAGACTGA GGCCGTTTAC CCACACCGCC GCCAAGCAGC 2340  
 TGCTCCCAT CGCCAACAAG CCGTGCTCT TCTACGCGCT GGAGTCCCTC GCCGCGGCGG 2400  
 GTGTCCGGGA GCGCGCGCTC GTCGTGGGCG CGTACGGCCG GGAGATCCGC GAACTCACCG 2460  
 GCGACGGCAC CGCGTTCGGG TTACGCATCA CCTACCTCCA CCAGCCCCGC CCGCTCGGTC 2520  
 TCGCGCACGC GGTGCGCATC GCGCGGGCT TCCTGGGCGA CGACGACTTC CTGCTGTACC 2580  
 TGGGGGACAA CTACCTGCCC CAGGGCGTCA CCGACTTCGC CCGCCAATCG GCCGCCGATC 2640  
 CCGCGGCGGC CCGGCTGCTG CTCACCCCGG TCGCGGACCC GTCCGCCCTC GCGCTCGCGG 2700  
 AGGTCGACGC GGACGGGAAC GTGCTGCGCT TGGAGGAGAA ACCCGACGTC CCGCGCAGCT 2760  
 CGCTCGCGCT CATCGGCGTG TACGCCCTCA GCGCGGCCGT CCACGAGGCG GTACGGGCCA 2820  
 TCACCCCTC CGCCCGCGG GAGCTGGAGA TCACCCACGC CGTGCAGTGG ATGATCGACC 2880  
 GGGGCTGCG CGTACGGGC GAGACCACCA CCGGCCCTG GCGCGACACC GGCAGCGCGG 2940  
 AGGACATGCT GGAGGTCAAC CGTCACGTCC TGGACGGACT GGAGGGCCGC ATCGAGGGGA 3000  
 AGGTCGACGC GCACAGCAG CTGGTCGGCC GGGTCCGGGT GCGCGAAGGC GCGATCGTGC 3060  
 GGGGGTCACA CGTGGTGGG CCGGTGGTGA TCGGCGCGGG TGCCGTGCTC AGCAACTCCA 3120  
 GTGTGCGCCC GTACACCTCC ATCGGGGAGG ACTGCCGGGT CGAGGACAGC GCCATCGAGT 3180  
 ACTCCGTCT GCTGCGCGG GCGCAGGTG AGGGGGCGTC CCGCATCGAG GCGTCCCTCA 3240  
 TCGGCGCGG CGCCGTGCTC GCGCGGCCC CCGTCTCCC GCAGGCTCAC CGACTGGTGA 3300  
 TCGGCGACCA CAGCAAGGTG TATCTCAGG CATGACCAG ACCATCCTCG TCACCGGCGG 3360  
 AGCGGGCTTC ATTCGTCCG CCTACGTCCG CCGGCTCTG TCGCCCGGG CCGCGGCGG 3420  
 CGTCGCGGTG ACCGTCTCG ACAAACCTAC CTACGCGGC AGCCTCGCC GCCTGCACGC 3480  
 GGTGCGTGAC CATCCCGGCC TCACCTTCGT CCAGGGCGAC GTGTGCGACA CCGCGCTCGT 3540  
 CGACACGCTG GCCGCGCGG ACGACGACAT CGTGCACTTC GCGGCCGAGT CGCACGTGGA 3600  
 CCGCTCCATC ACCGACAGG GTGCTTCAC CCGCACCAAC GTGCTGGGA CCCAGGTCT 3660  
 GCTCGACGCC GCGCTCCGCC ACGGTGTGCG CACCTTCGTG CACGTCTCCA CCGACGAGGT 3720  
 GTACGGCTCC CTCCCGCAG GGGCGCGCG GAGAGCGAC CCCCTGCTTC CGACCTCGCC 3780  
 GTACGCGCG TCGAAGGCG CCTCGGACCT CATGGCGCTC GCGCACCAAC GCACCCACGG 3840



CCTGGACGTC	CGGGTGACCC	GCTGTTGAA	CAACTTCGGC	CCCCACCAGC	ATCCCCAGAA	3900
GCTCATACCG	CGCTTCCTGA	CCAGCCTCCT	GTCCGGCGGC	ACCGTTCCCC	TCTACGGCGA	3960
CGGGCGGCAC	GTGCGCGACT	GGCTGCACGT	CGACGACCAC	GTCAGGGCCG	TCGAACTCGT	4020
CCCGTGTCG	GGCCGGCCGG	GAGAGATCTA	CAACATCGGG	GGCGGCACCT	CGCTGCCCAA	4080
CCTGGAGCTC	ACGCACCCGT	TGCTCGCACT	GTGCGGCGCG	GGCCCGGAGC	GCATCGTCCA	4140
CGTCGAGAAC	CGCAAGGGGC	ACGACCGGCG	CTACGCGGTC	GACCACAGCA	AGATCACCGC	4200
GGAACTCGGT	TACCGGCCGC	GCACCGACTT	CGCGACCGCG	CTGGCCGACA	CCGCGAAGTG	4260
GTACGAGCGG	CACGAGGACT	GGTGGCGTCC	CCTGCTCGCC	GCGACATGAC	GTCGGGCCGG	4320
ACCGCAACCA	CCGGCCCCCG	CCGGCACACC	GCCGCCCGCG	GCCGCTGGCC	GGCCGGTCAG	4380
CGTCCGTGAG	CCGGGCGCCG	GCCGCCCCGC	GGGCCGGCGG	CGGTGGACCC	CCGGACCACC	4440
AGTTCGGCA	TGAAGACGAA	TTCCGTGCGC	GGCGGCGGCG	TTCCGCTCAT	CTCCTCCAGC	4500
AGTGCGTCCA	CGGCGACCTG	CCCCATCGCC	TTGACGGGCT	GTCTGATGGT	GGTCAGGGGA	4560
GGGTTCGGTGA	AGGCCATGAG	CGGCGAGTCG	TCGAAGCCGA	CCACCAGAGT	GTCACCGGGA	4620
ACCGTGAGAC	CCCGCCGGCG	CGCGGCCCGC	ACGGCGCCGA	GGGCCATCAT	GTCGCTGGCG	4680
CACATGACGG	CGGTGCAGCC	CAGGTCGATC	AGCGCGGACG	CGGCGGCCTG	GCCCCCTCC	4740
AGGGAGAACA	GCGAGTGCTG	CACGAGCTCC	TCGGACTCCC	GCGCCGACAC	TCCAGGTGC	4800
TCCCGCACGC	CGGCCCGGAA	CCCCTCGATC	TTCCGCTGCA	CCGGCACGAA	GCGGGCGGGC	4860
CCGACGGCGA	GGCCGACGCG	CTCGTGCCCC	AGCTCCGCCA	GGTGCGCCAC	GGCCAGGCGC	4920
ATCGCGGCCC	GGTCGTCCGG	GGAGACGAAG	GGTGCCCTCA	TCCGGGGCGA	GAACCCGTTT	4980
ACGAGGACGA	AGGSCACCTG	CCGCTCGTGC	AGCCGGCCGT	ACCGTCCGGT	CTCGGCGGTG	5040
GTGTCCGCGT	GCAGTCCGGA	GACGAAGATG	ATGCCGGACA	CCCCGCGGTC	CACGAGCATC	5100
TCCGTGAGTT	CGTCTCGGT	CGAGCCGCCC	GGGTCTCGC	TGGCGAGCAC	GGGCGTGTAG	5160
CCCTGACGCG	TGAGCGCCTG	CCCCATCACC	TGGGCCAGTG	CGGGGAAGAA	GGGGTTGTCC	5220
AGTTCGGGGG	TGACCAGTCC	GACCAGCTCG	GCGCGGCGCT	GTCGCGCCCG	CTGCTCGTAG	5280
CCCAGCGCGT	CCAGTGCGGT	CAGCACCGAG	TCGCGGGTGC	CGGTGGCCAC	ACC CGCGCGCA	5340
CCGTTCAGCA	CCCGGCTGAC	CGTGGCCCTG	CTGACGCCCC	CCCGGGCTGC	GATGTCGGCG	5400
AGCCGCATGG	TCATGGCAAC	GCACTCTACC	TGTCGGGGCG	TCAGGGCGTG	CCCACCGCGC	5460
GCGGAACCGG	CGGACTGCGG	GGCACGGCCC	GTCCGCCGCC	CACGGACCAC	GCGCCCGAAA	5520
CGATGGCTGA	AAATGCTTGC	AGCAAATTGC	CGCAACGTCT	TTCCGGCGGCT	TTTCGATCCT	5580
GTTACGTTCC	TGGCAACCCC	GGCGCCGCGC	AGAAGCGGTT	GGCGTGAGGC	GTCCAGACCT	5640
CCGCCCCGATT	CCGGGATCAC	TCAGGGGAGT	TCACAATGCG	GCGTGGCATT	GCGGCCACCG	5700
CGCTGTTGCG	GGCTGTGGCC	ATGACGGCAT	CGGCGTGTGG	CGGGGGCGAC	AACGGCGGAA	5760
GCGGTACCGA	CGCGGGCGGC	ACGGAGCTGT	CGGGGACCGT	CACCTTCTGG	GACACGTCCA	5820
ACGAAGCCGA	GAAGGCGACG	TACCAGGCCC	TCGCGGAGGG	CTTCGAGAAG	GAGCACCCGA	5880

AGGTCGACGT CAAGTACGTC AACGTCCCGT TCGGCGAGGC GAACGCCAAG TTCAAGAACG 5940  
CCGCGGGCGG CAACTCCGGT GCGCCGGACG TGATGCGTAC GGAGGTCGCC TGGGTCGCGG 6000  
ACTTCGCCAG CATCGGCTAC CTCGCCCCGC TCGACGGCAC GCGCGCCCTC GACGACGGGT 6060  
CGGACCACCT TCCCCAGGGC GGCAGCACCA GGTACGAGGG GAACACCTAC GCGGTCCCGC 6120  
AGGTGATCGA CACCCTGGCG CTCTTCTACA ACAAGGAACT GCTGACGAAG GCCGGTGTCTG 6180  
AGGTGCCGGG CTCCCTCGCC GAGCTGAAGA CGGCCGCCGC CGAGATCACC GAGAAGACCG 6240  
GCGCGAGCGG CCTCTACTGC GGGGCGACGA CCCGTACTTG GTTCCTGCCC TACCTCTACG 6300  
GGGAGGGCGG CGACCTGGTC GACGAGAAGA ACAAGACCGT CACGGTCGAC GACGAAGCCG 6360  
GTGTGCGCGC CTACCGCGTC ATCAAGGACC TCGTGGACAG CAAGGCGGCC ATCACCACG 6420  
CGTCCGACGG CTGGAACAAC ATGCAGAAGC CTTTCAAGTC GGGCAAGGTC GCCATGATGG 6480  
TCAACGGCCC CTGGGCCATC GAGGACGTCA AGGCGGGAGC CCGCTTCAAG GACGCCGGCA 6540  
ACCTGGGGGT CGCCCCCGTC CCGGCCGGCA GTGCCGGACA GGGCTCTCCC CAGGGCGGGT 6600  
GGAACCTCTC GGTGTACGCG GGCTCGAAGA ACCTCGACGC CTCCTACGCC TTCGTGAAGT 6660  
ACATGAGCTC CGCCAAGGTG CAGCAGCAGA CCACCGAGAA GCTGAGCCTG CTGCCCACCC 6720  
GCACGTCCGT CTACGAGGTC CCGTCCGTCG CGGACAACGA GATGGTGAAG TTCTTCAAGC 6780  
CGGCCGTCTG CAAGGCCGTC GAACGGCCGT GGATCGCCGA GGGCAATGCC CTCTTCGAGC 6840  
CGATCCGGCT GCAG 6854

(2) INFORMATION FOR SEQ ID NO.: 8:

(i) SEQUENCE CHARACTERISTICS:

5

- (A) LENGTH: 240 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

10

(ii) MOLECULE TYPE: protein

(ix) FEATURES:

- (A) NAME/KEY: acbA
- (B) LOCATION: 1..240

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO.: 8:

Val Ile Val Ala Glu His Leu Val Lys Glu Phe Arg Leu Ala Glu Arg  
 1 5 10 15  
 Glu Pro Gly Leu Leu Gly Ser Leu Ser Thr Leu Leu Thr Arg Arg Tyr  
 20 25 30  
 Arg Val Val Arg Ala Val Asp Asp Val Ser Phe Glu Ile Pro Ala Gly  
 35 40 45  
 Thr Lys Thr Ala Tyr Ile Gly Ala Asn Gly Ala Gly Lys Ser Thr Thr  
 50 55 60  
 Ile Lys Met Leu Thr Gly Ile Met Thr Pro Thr Ser Gly Arg Cys Thr  
 65 70 75 80  
 Val Ala Gly Leu Glu Pro Tyr Arg His Arg Gln Arg Asn Ala Arg Thr  
 85 90 95  
 Ile Gly Val Val Phe Gly Gln Arg Ser Gln Leu Trp Trp Asp Leu Ser  
 100 105 110  
 Val Pro Asp Ser Phe Arg Ile Leu Arg Arg Ile Tyr Asp Ile Pro Gly  
 115 120 125  
 Pro Val Tyr Arg Arg Asn Leu Ala Leu Phe Arg Asp Leu Leu Asp Ile  
 130 135 140  
 Asp Ala Leu Gly Ser Thr Pro Val Arg Gln Leu Ser Leu Gly Gln Arg  
 145 150 155 160  
 Met Arg Ala Glu Ile Ala Ala Ser Leu Leu His Asp Pro Ala Val Leu  
 165 170 175  
 Phe Trp Asp Glu Pro Thr Ile Gly Leu Asp Met Val Leu Lys Asp Ala  
 180 185 190  
 Val Arg Arg Leu Val Asn Arg Ala His Arg Glu Leu Gly Thr Thr Val  
 195 200 205  
 Val Leu Thr Ser His Asp Ile Ala Asp Ile Ala Ala Ile Cys Asp Ser  
 210 215 220  
 Ala Leu Val Val Asp Gln Gly Arg Val Val His Gln Gly Thr Leu Gln  
 225 230 235 240

## (2) INFORMATION FOR SEQ ID NO.: 9:

- 5 (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 429 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear
- 10 (ii) MOLECULE TYPE: protein
- (ix) FEATURES:
- (A) NAME/KEY: acbB
  - (B) LOCATION: 1..429
- 15

Met	Thr	Gly	Leu	Arg	Gln	Thr	Gln	His	Leu	Ala	Arg	Glu	Ala	Arg	His
1				5					10					15	
Leu	Ala	Pro	Gly	Ala	Ser	Glu	Glu	Ala	Val	His	Gly	Arg	Arg	Val	Phe
			20					25					30		
Ala	Glu	Gly	Arg	Gly	Pro	Val	Leu	Thr	Asp	Leu	Asp	Gly	Asn	Gln	Tyr
		35					40					45			
Leu	Asp	Phe	Ala	Ala	Gly	Thr	Leu	Thr	Gln	Ser	Leu	Gly	His	Gly	His
	50					55					60				
Pro	Glu	Val	Val	Glu	Ala	Leu	Thr	Thr	Gln	Ala	Arg	Arg	Leu	Trp	Asn
65					70					75					80
Val	His	Asp	Ser	Ala	Thr	Pro	Asp	Arg	Ala	Gly	Leu	Leu	Glu	Leu	Leu
				85					90					95	

Ala Arg Leu Leu Pro Glu Gln Leu Asp Thr Tyr Ala Phe Phe Ser Thr  
 100 105 110  
 Gly Ala Glu Val Val Glu Ala Ala Leu Arg Val Val Gln Ala Thr Ala  
 115 120 125  
 Ala Pro Gly Arg Asn Arg Ile Cys Ala Leu Arg His Gly Phe His Gly  
 130 135 140  
 Lys Thr Met Gly Ala Arg Met Leu Val His Trp Asp Ile Gly His Gln  
 145 150 155 160  
 Ala Phe Ser Gly Asn Ser Val Leu Ala Thr Ala Pro Thr Gly Tyr Arg  
 165 170 175  
 Cys Pro Leu Gly Leu Glu Tyr Pro Ser Cys Asp Val Arg Cys Ala Thr  
 180 185 190  
 Leu Val Arg Arg His Ile Ala Glu Lys Pro Asn Val Ser Ala Leu Val  
 195 200 205  
 Phe Glu Pro Val Leu Gly Ala Ala Gly Val Ile Val Pro Pro Pro Gly  
 210 215 220  
 Tyr Trp Glu Arg Ile Ala Gly Ala Cys Arg Asp Gly Gly Val Leu Leu  
 225 230 235 240  
 Val Ala Asp Glu Val Leu Thr Gly Gly Gly Arg Thr Gly Ala Phe Leu  
 245 250 255  
 Ala Ser Glu Leu Phe Gly Ile Glu Pro Asp Leu Ala Met Leu Ser Lys  
 260 265 270  
 Gly Thr Ala Ser Gly Phe Pro Phe Ala Val Leu Ala Gly Arg Ala Glu  
 275 280 285  
 Ala Ala Gln Ala Gly Gly Gly His Pro Gly Ala Tyr Ala Ser Thr Tyr  
 290 295 300  
 Ala Ser Asn Pro Leu Gly Ile Ala Ala Ala Arg Ala Thr Leu Glu Val  
 305 310 315 320  
 Val Glu Arg Asp Arg Leu Ile Asp Arg Val Arg Val Leu Gly Glu Leu  
 325 330 335  
 Ile Gln Glu Arg Leu Arg Ala Leu Glu Ser Arg Phe Pro Gln Leu Gly  
 340 345 350  
 Gln Val Arg Gly Leu Gly Leu Leu Trp Gly Leu Glu Phe Val Thr Asp  
 355 360 365  
 Ala Val Gly Arg Ala Pro Ala Pro Glu Thr Ala Arg Ala Val Tyr Thr  
 370 375 380  
 Thr Ala Leu Asp Leu Gly Leu Arg Thr Ser Leu Gly Gly His Ile Leu  
 385 390 395 400  
 Arg Leu Ala Pro Pro Phe Thr Leu Asp Glu Ala Leu Leu Asp Glu Gly  
 405 410 415  
 Leu Arg Leu Leu Glu Thr Ala Val Glu Arg Val Ile Ala  
 420 425

(2) INFORMATION FOR SEQ ID NO.: 10:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 355 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

5

(ii) MOLECULE TYPE: protein

(ix) FEATURES:

(A) NAME/KEY: acbC

10

(B) LOCATION: 1..355

(xi) SEQUENCE DESCRIPTION: SEQ ID NO.: 10:

[illegible]

[illegible]

## (2) INFORMATION FOR SEQ ID NO.: 11:

## (i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 325 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

10

## (ix) FEATURES:

- (A) NAME/KEY: acbD  
 (B) LOCATION: 1..325

## 15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO.: 11:

Met Thr Thr Thr Ile Leu Val Thr Gly Gly Ala Gly Phe Ile Arg Ser  
 1 5 10 15  
 Ala Tyr Val Arg Arg Leu Leu Ser Pro Gly Ala Pro Gly Gly Val Ala  
 20 25 30  
 Val Thr Val Leu Asp Lys Leu Thr Tyr Ala Gly Ser Leu Ala Arg Leu  
 35 40 45  
 His Ala Val Arg Asp His Pro Gly Leu Thr Phe Val Gln Gly Asp Val  
 50 55 60  
 Cys Asp Thr Ala Leu Val Asp Thr Leu Ala Ala Arg His Asp Asp Ile  
 65 70 75 80  
 Val His Phe Ala Ala Glu Ser His Val Asp Arg Ser Ile Thr Asp Ser  
 85 90 95  
 Gly Ala Phe Thr Arg Thr Asn Val Leu Gly Thr Gln Val Leu Leu Asp  
 100 105 110  
 Ala Ala Leu Arg His Gly Val Arg Thr Phe Val His Val Ser Thr Asp  
 115 120 125  
 Glu Val Tyr Gly Ser Leu Pro His Gly Ala Ala Ala Glu Ser Asp Pro  
 130 135 140

T02080-EP9702826



Leu Leu Pro Thr Ser Pro Tyr Ala Ala Ser Lys Ala Ala Ser Asp Leu  
 145 150 155 160  
 Met Ala Leu Ala His His Arg Thr His Gly Leu Asp Val Arg Val Thr  
 165 170 175  
 Arg Cys Ser Asn Asn Phe Gly Pro His Gln His Pro Glu Lys Leu Ile  
 180 185 190  
 Pro Arg Phe Leu Thr Ser Leu Leu Ser Gly Gly Thr Val Pro Leu Tyr  
 195 200 205  
 Gly Asp Gly Arg His Val Arg Asp Trp Leu His Val Asp Asp His Val  
 210 215 220  
 Arg Ala Val Glu Leu Val Arg Val Ser Gly Arg Pro Gly Glu Ile Tyr  
 225 230 235 240  
 Asn Ile Gly Gly Gly Thr Ser Leu Pro Asn Leu Glu Leu Thr His Arg  
 245 250 255  
 Leu Leu Ala Leu Cys Gly Ala Gly Pro Glu Arg Ile Val His Val Glu  
 260 265 270  
 Asn Arg Lys Gly His Asp Arg Arg Tyr Ala Val Asp His Ser Lys Ile  
 275 280 285  
 Thr Ala Glu Leu Gly Tyr Arg Pro Arg Thr Asp Phe Ala Thr Ala Leu  
 290 295 300  
 Ala Asp Thr Ala Lys Trp Tyr Glu Arg His Glu Asp Trp Trp Arg Pro  
 305 310 315 320  
 Leu Leu Ala Ala Thr  
 325

(2) INFORMATION FOR SEQ ID NO.: 12:

(i) SEQUENCE CHARACTERISTICS:

- 5
- (A) LENGTH: 345 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: protein

(ix) FEATURES:

- (A) NAME/KEY: acbE
- (B) LOCATION: 1..345

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO.: 12:

Met	Thr	Met	Arg	Leu	Ala	Asp	Ile	Ala	Ala	Arg	Ala	Gly	Val	Ser	Lys
1				5					10					15	
Ala	Thr	Val	Ser	Arg	Val	Leu	Asn	Gly	Ala	Arg	Gly	Val	Ala	Thr	Gly
			20					25					30		
Thr	Arg	Asp	Ser	Val	Leu	Thr	Ala	Leu	Asp	Ala	Leu	Gly	Tyr	Glu	Gln
		35					40					45			
Pro	Ala	Arg	Gln	Arg	Arg	Ala	Glu	Leu	Val	Gly	Leu	Val	Thr	Pro	Glu
	50					55					60				
Leu	Asp	Asn	Pro	Phe	Phe	Pro	Ala	Leu	Ala	Gln	Val	Met	Gly	Gln	Ala
65					70					75					80
Leu	Thr	Arg	Gln	Gly	Tyr	Thr	Pro	Val	Leu	Ala	Thr	Gln	Thr	Pro	Gly
				85					90					95	
Gly	Ser	Thr	Glu	Asp	Glu	Leu	Thr	Glu	Met	Leu	Val	Asp	Arg	Gly	Val
			100					105					110		
Ser	Gly	Ile	Ile	Phe	Val	Ser	Gly	Leu	His	Ala	Asp	Thr	Thr	Ala	Glu
	115						120					125			
Thr	Gly	Arg	Tyr	Gly	Arg	Leu	His	Glu	Arg	Gln	Val	Pro	Phe	Val	Leu
	130					135					140				
Val	Asn	Gly	Phe	Ser	Pro	Arg	Ile	Glu	Ala	Pro	Phe	Val	Ser	Pro	Asp
145					150					155					160
Asp	Arg	Ala	Ala	Met	Arg	Leu	Ala	Val	Ala	His	Leu	Ala	Glu	Leu	Gly
				165					170					175	
His	Glu	Arg	Val	Gly	Leu	Ala	Val	Gly	Pro	Ala	Arg	Phe	Val	Pro	Val
			180					185					190		
Gln	Arg	Lys	Ile	Glu	Gly	Phe	Arg	Ala	Gly	Val	Arg	Glu	His	Leu	Gly
		195					200					205			
Val	Ser	Ala	Arg	Glu	Ser	Glu	Glu	Leu	Val	Gln	His	Ser	Leu	Phe	Ser
	210					215					220				
Leu	Glu	Gly	Gly	Gln	Ala	Ala	Ala	Ser	Ala	Leu	Ile	Asp	Leu	Gly	Cys
225					230					235					240
Thr	Ala	Val	Met	Cys	Ala	Ser	Asp	Met	Met	Ala	Leu	Gly	Ala	Val	Arg
				245					250					255	
Ala	Ala	Arg	Arg	Arg	Gly	Leu	Thr	Val	Pro	Gly	Asp	Ile	Ser	Val	Val
			260					265					270		
Gly	Phe	Asp	Asp	Ser	Pro	Leu	Met	Ala	Phe	Thr	Asp	Pro	Pro	Leu	Thr
		275					280					285			
Thr	Ile	Arg	Gln	Pro	Val	Lys	Ala	Met	Gly	Gln	Val	Ala	Val	Asp	Ala
	290					295					300				
Leu	Leu	Glu	Glu	Met	Ser	Gly	Thr	Pro	Pro	Pro	Arg	Thr	Glu	Phe	Val
305					310					315					320
Phe	Met	Pro	Glu	Leu	Val	Val	Arg	Gly	Ser	Thr	Ala	Ala	Gly	Pro	Arg
				325					330					335	
Gly	Gly	Arg	Arg	Pro	Ala	His									

5 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 393 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: protein

(ix) FEATURES:  
(A) NAME/KEY: acbF  
(B) LOCATION: 1..393

15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO.: 13:

Met Arg Arg Gly Ile Ala Ala Thr Ala Leu Phe Ala Ala Val Ala Met  
 1 5 10 15  
 Thr Ala Ser Ala Cys Gly Gly Gly Asp Asn Gly Gly Ser Gly Thr Asp  
 20 25 30  
 Ala Gly Gly Thr Glu Leu Ser Gly Thr Val Thr Phe Trp Asp Thr Ser  
 35 40 45  
 Asn Glu Ala Glu Lys Ala Thr Tyr Gln Ala Leu Ala Glu Gly Phe Glu  
 50 55 60  
 Lys Glu His Pro Lys Val Asp Val Lys Tyr Val Asn Val Pro Phe Gly  
 65 70 75 80  
 Glu Ala Asn Ala Lys Phe Lys Asn Ala Ala Gly Gly Asn Ser Gly Ala  
 85 90 95  
 Pro Asp Val Met Arg Thr Glu Val Ala Trp Val Ala Asp Phe Ala Ser  
 100 105 110  
 Ile Gly Tyr Leu Ala Pro Leu Asp Gly Thr Pro Ala Leu Asp Asp Gly  
 115 120 125  
 Ser Asp His Leu Pro Gln Gly Gly Ser Thr Arg Tyr Glu Gly Lys Thr  
 130 135 140  
 Tyr Ala Val Pro Gln Val Ile Asp Thr Leu Ala Leu Phe Tyr Asn Lys  
 145 150 155 160  
 Glu Leu Leu Thr Lys Ala Gly Val Glu Val Pro Gly Ser Leu Ala Glu  
 165 170 175  
 Leu Lys Thr Ala Ala Ala Glu Ile Thr Glu Lys Thr Gly Ala Ser Gly  
 180 185 190  
 Leu Tyr Cys Gly Ala Thr Thr Arg Thr Trp Phe Leu Pro Tyr Leu Tyr  
 195 200 205  
 Gly Glu Gly Gly Asp Leu Val Asp Glu Lys Asn Lys Thr Val Thr Val  
 210 215 220  
 Asp Asp Glu Ala Gly Val Arg Ala Tyr Arg Val Ile Lys Asp Leu Val  
 225 230 235 240  
 Asp Ser Lys Ala Ala Ile Thr Asp Ala Ser Asp Gly Trp Asn Asn Met  
 245 250 255  
 Gln Asn Ala Phe Lys Ser Gly Lys Val Ala Met Met Val Asn Gly Pro  
 260 265 270  
 Trp Ala Ile Glu Asp Val Lys Ala Gly Ala Arg Phe Lys Asp Ala Gly  
 275 280 285  
 Asn Leu Gly Val Ala Pro Val Pro Ala Gly Ser Ala Gly Gln Gly Ser  
 290 295 300  
 Pro Gln Gly Gly Trp Asn Leu Ser Val Tyr Ala Gly Ser Lys Asn Leu  
 305 310 315 320

0992683-030701  
 T02030-030701

Asp Ala Ser Tyr Ala Phe Val Lys Tyr Met Ser Ser Ala Lys Val Gln  
325 330 335

Gln Gln Thr Thr Glu Lys Leu Ser Leu Leu Pro Thr Arg Thr Ser Val  
340 345 350

Tyr Glu Val Pro Ser Val Ala Asp Asn Glu Met Val Lys Phe Phe Lys  
355 360 365

Pro Ala Val Asp Lys Ala Val Glu Arg Pro Trp Ile Ala Glu Gly Asn  
370 375 380

Ala Leu Phe Glu Pro Ile Arg Leu Gln  
385 390

104080 88922560